Nucleic acid modulation of ApoE

By designing RNA nucleic acids complementary to the APOE gene and delivering them using an AAV vector, the problem of excessive APOE protein expression in Alzheimer's disease was solved, achieving reversal of neuropathology and slowing of disease progression.

CN119032174APending Publication Date: 2024-11-26UNIQURE BIOPHARMA BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033802.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-17
Filing Date
2023-04-12
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Currently, there is a lack of effective treatments for Alzheimer's disease, especially due to the increased risk of disease caused by single nucleotide polymorphisms in the APOE gene. Existing technologies cannot effectively reduce the expression of APOE protein to slow or reverse the progression of neuropathology.

Method used

By designing a nucleic acid containing two RNA-coding sequences, one of which is partially complementary to the APOE gene and the other supporting the expression of the first RNA, the APOE gene can be silenced. This can be delivered to target cells using an AAV vector to reduce the expression of APOE protein.

Benefits of technology

It effectively reduces the expression of APOE protein, decreases the formation of amyloid plaques, reverses or prevents neuropathology, slows disease progression, and is suitable for APOE ε4 allele carriers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005080622200000221
    Figure BDA0005080622200000221
  • Figure BDA0005080622200000231
    Figure BDA0005080622200000231
  • Figure BDA0005080622200000241
    Figure BDA0005080622200000241
Patent Text Reader

Abstract

The present invention relates to a nucleic acid comprising two RNA coding sequences, wherein each RNA comprises a hairpin and a guide sequence substantially complementary to a portion of the APOE gene; and related AAVs, compositions, pharmaceutical compositions and their use in therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the fields of biotechnology, medicine and gene therapy. The present invention relates to nucleic acids comprising two or more RNA coding sequences, wherein one RNA coding sequence contains a guide sequence that is substantially complementary to a portion of an APOE gene); related compositions, pharmaceutical compositions and their use in treatment. Background Art

[0002] Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is considered to be the main cause of dementia in adults (Van Cauwenberghe et al. 2016, Genet Med. [Medical Genetics]; 18: 421: 30). The disease is characterized by the accumulation of extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles, which cause neuronal cell death and glial cell activation, ultimately leading to reduced brain function. The formation of amyloid plaques is due to the cleavage of amyloid precursor protein (APP) by β-secretase and γ-secretase. The formation of neurofibrillary tangles is instead due to the misfolding of tau protein (Pospich and Raunser 2017, Science [Science]; 358: 45-46).

[0003] One of the genetic factors that increase the risk of AD is related to the human apolipoprotein (APOE) gene. The human APOE gene has a single nucleotide polymorphism (SNP), which produces the following three major allele variants: ε2, ε3 and ε4 (i.e., APOE subtypes E2, E3 and E4) (Belbin et al. 2007, Hum Mol Genet. [Human Molecular Genetics]; 16: 2199-208). The ε4 variant is involved in late-onset AD (LOAD), and carriers of APOEε4 increase the risk of AD onset in an allele number-dependent manner, i.e., one APOEε4 allele advances the age of onset by an average of 2-5 years, while the presence of two APOEε4 alleles advances the onset by 5-10 years. Importantly, 40%-65% of AD patients carry at least one APOEε4 allele. In addition, it has also been observed that APOE4 is associated with adverse outcomes in atherosclerosis, craniocerebral injury (TBI) and other diseases. In contrast, APOEε2 and / or APOEε3 alleles exert protective or neutral effects on the development of AD (Yamazaki et al. 2016, CNS Drugs [CNS Drugs].; 30:773-89).

[0004] The APOE protein encoded by the APOE gene is a secretory lipid transporter found in peripheral and central body systems such as the central nervous system (CNS). In the periphery, APOE is mainly secreted by hepatocytes, while in the CNS, astrocytes are the main source of APOE (Chernick et al. 2019, Neurosci Lett. [Neuroscience Express]; 708: 134306).

[0005] SNPs in the APOE gene induce differences in amino acid residues located at positions 130 and 176 (also referred to as positions 112 and 158, respectively, when the signal peptide of the protein is not included) (APOE ε2, Cys112 / Cys158; APOE ε3, Cys112 / Arg158; APOE ε4, Arg112 / Arg158). These single amino acid polymorphisms are believed to severely affect the structure and function of APOE, thereby affecting Aβ metabolism, aggregation, deposition, and tau protein phosphorylation. (Liu et al. 2013, Nat Rev Neurol. [Nature Review Neurology]; 9: 106-18).

[0006] Considering the complex pathophysiology of AD and the associated gene regulatory networks, there are currently no promising therapies for the treatment of AD, and thus there is an urgent need to find such therapies. Summary of the invention

[0007] The present invention solves this problem by applying nucleic acid technology, wherein the nucleic acid comprises two or more RNA coding sequences, wherein one RNA coding sequence contains a guide sequence that is substantially complementary to a portion of the APOE gene, and the other RNA coding sequence supports the expression of the first RNA coding sequence, possibly by cluster formation. Thus, increasing the silencing of the APOE gene.

[0008] In one aspect, an expression cassette is provided, comprising a nucleic acid according to the invention, wherein the expression cassette is a DNA molecule.

[0009] In one aspect, an adeno-associated virus (AAV) vector is provided, comprising an expression cassette according to the present invention.

[0010] In one aspect, a pharmaceutical composition is provided, comprising a nucleic acid according to the invention, an expression cassette according to the invention, or an AAV vector according to the invention and at least one pharmaceutically acceptable excipient.

[0011] In one aspect, a nucleic acid according to the invention, or an expression cassette according to the invention, or an AAV vector according to the invention, or a pharmaceutical composition according to the invention is provided for use as a medicament.

[0012] In one aspect, a kit is provided, comprising a nucleic acid according to the invention, or an expression cassette according to the invention, or an AAV vector according to the invention, or a pharmaceutical composition according to the invention, wherein the kit further comprises an immunosuppressant.

[0013] In one aspect, an expression cassette is provided, comprising a nucleic acid encoding one or more APOE2 and APOE3 proteins selected from SEQ ID NOs. 249-254 for use in gene therapy. DETAILED DESCRIPTION

[0014] definition

[0015] Unless otherwise defined, technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Those skilled in the art will recognize many methods and materials similar or equivalent to the methods and materials described herein that can be used in the practice of the present invention. In fact, the present invention is in no way limited to this method.

[0016] In this document and its claims, the verb "to comprise" and its conjugations are used in its non-limiting sense to mean including items following the word, but not excluding items not specifically mentioned. Furthermore, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element is present, unless the context clearly requires that one and only one of the element is present. Thus, the indefinite article "a" or "an" generally means "at least one".

[0017] For the purposes of the present invention, the term “obtained” is considered to be a preferred embodiment of the term “obtainable.” If in the following for example an antibody is defined as being obtainable from a particular source, this should also be understood as disclosing the antibody obtained from this source.

[0018] As used herein, the term "and / or" indicates that one or more of the stated circumstances may occur alone or in combination with at least one of the stated circumstances, up to and including all of the stated circumstances.

[0019] As used herein, "at least" a particular value means the particular value or more. For example, "at least 2" is understood to be the same as "2 or more" (i.e., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ... etc.).

[0020] The word "about" or "approximately" when used in conjunction with a numerical value (eg, about 10) preferably means that the value may be plus or minus 0.1% of the given value (10).

[0021] As used herein, "effective amount" means the amount of the medicament required for improving the symptoms of the disease relative to untreated patients. The effective amount of one or more active agents used to practice the present invention for therapeutic treatment of cancer, for example, depends on the mode of administration, and varies with the age, weight and general health of the subject. Ultimately, the attending physician or veterinarian will determine the appropriate amount and dosage regimen. Such an amount is referred to as an "effective" amount, which can be determined as genome copies / kilogram (GC / kg). Therefore, in conjunction with the use of a drug, the drug is an "effective" indication for a disease or condition in the context of the present disclosure, and is used in a clinically appropriate manner to produce a beneficial effect on at least a statistically significant portion of patients, such as symptom improvement, cure, at least one disease sign or symptom alleviation, life extension, quality of life improvement, or other effects generally considered positive by doctors familiar with treating a particular type of disease or condition.

[0022] As described in this document, the use of a substance as a medicament may also be interpreted as the use of the substance in the manufacture of a medicament. Similarly, whenever a substance is used for treatment or as a medicament, it may also be used to manufacture a medicament for treatment. Products for use as medicaments described herein may be used in methods of treatment, wherein such methods of treatment include administering the product for use.

[0023] The terms "homology", "sequence identity" and the like are used interchangeably herein. Sequence identity is defined herein as the relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. The "similarity" between two amino acid sequences is determined by comparing the amino acid sequence of one polypeptide and its conservative amino acid substitutes with the sequence of a second polypeptide. "Identity" and "similarity" can be easily calculated by known methods.

[0024] "Sequence identity" and "sequence similarity" can be determined by comparing two peptides or two nucleotide sequences using a global or local alignment algorithm, depending on the length of the two sequences. It is preferred to use a global alignment algorithm (e.g., Needleman Wunsch) to compare sequences of similar length, which best align sequences over the entire length; and it is preferred to use a local alignment algorithm (e.g., Smith-Waterman) to compare sequences of greatly different lengths. When sequences (when optimally aligned using default parameters by, for example, programs GAP or BESTFIT) have at least a certain minimum percentage of sequence identity (as defined below), they can be referred to as "substantially identical" or "substantially similar". GAP uses the Needleman and Wunsch global alignment algorithm to compare two sequences over their entire length (full length), maximizing the number of matches and minimizing the number of gaps. When two sequences have similar lengths, global alignment is applicable to determining sequence identity. Typically, GAP default parameters are used, with gap creation penalty = 50 (nucleotides) / 8 (proteins), and gap extension penalty = 3 (nucleotides) / 2 (proteins). For nucleotides, the default scoring matrix used is nwsgapdna, and for proteins, the default scoring matrix is ​​Blosum62 (Henikoff and Henikoff, 1992, PNAS [Proceedings of the National Academy of Sciences of the United States of America] 89, 915-919). Sequence alignments and percent sequence identity scores can be determined as follows: using a computer program such as the GCG Wisconsin software package version 10.3 available from Accelrys Inc., 9685 Scranton Road, San Diego, CA 92121-3752, USA; or using open source software such as the program "needle" (using the global Needleman-Wunsch algorithm) or "water" (using the local Smith-Waterman algorithm) in EmbossWIN version 2.10.0, using the same parameters as GAP above, or using the default settings (both for "needle" and "water", and both for protein and DNA alignments, the default gap opening penalty is 10.0, and the default gap extension penalty is 0.5; for proteins, the default scoring matrix is ​​Blossum62; and for DNA, the default scoring matrix is ​​DNAFull). When the sequences have a widely different overall length, local alignments, such as local alignments using the Smith-Waterman algorithm, are preferred.

[0025] Alternatively, the similarity or identity percentage can be determined by searching public databases using algorithms such as FASTA, BLAST, etc. Thus, the nucleic acid and protein sequences of the invention can be further used as "query sequences" to search public databases, for example to identify other family members or related sequences. Such searches can be performed using the BLASTn and BLASTx programs (version 2.0) of Altschul et al. (1990) J. Mol. Biol. [Journal of Molecular Biology] 215: 403-10. BLAST nucleotide searches can be performed with the NBLAST program (score = 100, word length = 12) to obtain nucleotide sequences homologous to the oxidoreductase nucleic acid molecules of the invention. BLAST protein searches can be performed with the BLASTx program (score = 50, word length = 3) to obtain amino acid sequences homologous to the protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be used as described in Altschul et al. (1997) Nucleic Acids Res. 25(17):3389-3402. When using BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTx and BLASTn) can be used. See the homepage of the National Center for Biotechnology Information. http: / / www.ncbi.nlm.nih.gov / .

[0026] As used herein, the terms "selectively hybridizing," "selectively hybridizes selectively," and similar terms are intended to describe hybridization and washing conditions under which nucleotide sequences that are at least 66%, at least 70%, at least 75%, at least 80%, more preferably at least 85%, even more preferably at least 90%, preferably at least 95%, more preferably at least 98%, or more preferably at least 99% homologous to each other typically remain hybridized to each other. That is, such hybridizing sequences may have at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, more preferably at least 85%, even more preferably at least 90%, more preferably at least 95%, more preferably at least 98%, or more preferably at least 99% sequence identity.

[0027] A preferred, non-limiting example of such hybridization conditions is hybridization in 6X sodium chloride / sodium citrate (SSC) at about 45°C, followed by one or more washes in 1X SSC, 0.1% SDS at about 50°C, preferably at about 55°C, preferably at about 60°C, and even more preferably at about 65°C. Highly stringent conditions include, for example, hybridization in 5x SSC / 5xDenhardt solution / 1.0% SDS at about 68°C, and washing in 0.2x SSC / 0.1% SDS at room temperature. Alternatively, washing can be performed at 42°C.

[0028] The skilled person will know which conditions are suitable for stringent and highly stringent hybridization conditions. Additional guidance on such conditions is readily available in the art, such as in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, New York; and Ausubel et al. (eds.), Sambrook and Russell (2001) "Molecular Cloning: A Laboratory Manual" (3rd ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, New York).

[0029] Of course, polynucleotides that hybridize only to a poly (A) sequence (such as the 3' terminal poly (A) tract of mRNA) or a complementary stretch of T (or U) residues will not be included in the polynucleotides of the present invention used to specifically hybridize to a portion of a nucleic acid of the present invention, because such polynucleotides will hybridize to any nucleic acid molecule containing a poly (A) stretch or its complement (for example, virtually any double-stranded cDNA clone).

[0030] "Nucleic acid construct" or "nucleic acid vector" should be understood herein to mean an artificial nucleic acid molecule produced using recombinant DNA technology. Therefore, the term "nucleic acid construct" does not include naturally occurring nucleic acid molecules, although nucleic acid constructs can include (a part of) naturally occurring nucleic acid molecules. "Vector" is a nucleic acid construct (typically DNA or RNA) for transferring an exogenous nucleic acid sequence (i.e., DNA or RNA) into a host cell. The vector is preferably maintained in the host by autonomous replication and integration into at least one of the genomes of the host cell. The term "expression vector" or "expression construct" refers to a nucleotide sequence that can affect the expression of a gene in a host cell or host organism compatible with such a sequence. These expression vectors typically include at least one "expression cassette", which is a functional unit that can affect the expression of a sequence encoding a product to be expressed, and wherein the coding sequence is operably connected to an appropriate expression control sequence, which at least includes a suitable transcriptional regulatory sequence and optionally a 3' transcription termination signal. There may also be other factors that are necessary or helpful in achieving expression, such as expression enhancer elements. The expression vector will be introduced into a suitable host cell, and can affect the expression of the coding sequence in the in vitro cell culture of the host cell. Preferred expression vectors will be suitable for expressing viral proteins and / or nucleic acids, particularly recombinant AAV proteins and / or nucleic acids.

[0031] As used herein, the term "promoter" or "transcription regulatory sequence" refers to a nucleic acid fragment that acts to control the transcription of one or more coding sequences and is located upstream in the direction of transcription relative to the transcription start site of the coding sequence and is structurally identified by the presence of a binding site for a DNA-dependent RNA polymerase, a transcription start site, and any other DNA sequence, including but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other nucleotide sequence known to those skilled in the art that acts directly or indirectly to regulate the amount of transcription from the promoter. A "constitutive" promoter is a promoter that is active in most tissues under most physiological and developmental conditions. An "inducible" promoter is a promoter that is physiologically or developmentally regulated (e.g., by the application of a chemical inducer or a biological entity).

[0032] The term "reporter" may be used interchangeably with marker, although it is primarily used to refer to visible markers, such as green fluorescent protein (GFP) or luciferase.

[0033] The terms "protein" or "polypeptide" are used interchangeably and refer to a molecule consisting of a chain of amino acids without reference to a particular mode of action, size, three-dimensional structure, or origin.

[0034] The term "gene" means a DNA fragment that is contained in a region (transcribed region) that is operably connected to a suitable regulatory region (e.g., a promoter) that is transcribed into an RNA molecule (e.g., mRNA) in a cell. A gene will typically contain several operably connected fragments, such as a promoter, a 5' leader sequence, a coding region, and a 3' non-translated sequence (3' end) containing a polyadenylation site. "Gene expression" refers to a process in which a DNA region that is operably connected to a suitable regulatory region, particularly a promoter, is transcribed into a biologically active RNA, i.e., an RNA that can be translated into a biologically active protein or peptide.

[0035] The term "homologous" when used to indicate the relationship between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell is to be understood as meaning that in nature, the nucleic acid or polypeptide molecule is produced by a host cell or organism of the same species (preferably the same breed or strain). If homologous to a host cell, the recombinant nucleic acid or polypeptide molecule is homologous to the host cell.

[0036] The nucleotide sequence of the code polypeptide will typically (but not necessarily) be operably connected to another (heterologous) promoter sequence and (if applicable) another (heterologous) secretion signal sequence and / or terminator sequence different from its natural environment. It should be understood that regulatory sequences, signal sequences, terminator sequences, etc. can also be homologous to host cells. In this context, only "homologous" sequence elements are used to allow construction of "self-cloning" genetically modified organisms (GMOs) (self-cloning as defined in European Directive 98 / 81 / EC Annex II). When used to indicate the correlation of two nucleic acid sequences, the term "homologous" means that a single-stranded nucleic acid sequence can hybridize with a complementary single-stranded nucleic acid sequence. The degree of hybridization may depend on a variety of factors, including the amount of identity between the sequences and hybridization conditions (such as temperature and salt concentration discussed later).

[0037] The terms "heterologous" and "exogenous" when used with respect to nucleic acids (DNA or RNA) or proteins refer to such nucleic acids or proteins that are not naturally present as part of an organism, cell, genome or DNA or RNA sequence in which it is present, or that are found in one or more positions in a cell or genome or DNA or RNA sequence different from that in which it is found in nature. Heterologous and exogenous nucleic acids or proteins are not endogenous to the cells in which they are introduced, but have been obtained or synthesized or recombinantly produced from another cell. Typically, although not necessarily, such nucleic acid encodings are not usually produced by cells that transcribe or express DNA, i.e., exogenous proteins. Similarly, exogenous RNA encodings are not usually expressed in cells in which exogenous RNA is present. Heterologous / exogenous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that is foreign to the cell expressing it that will be recognized by those skilled in the art is covered by the term heterologous or exogenous nucleic acids or proteins herein. The terms heterologous and exogenous also apply to non-natural combinations of nucleic acid or amino acid sequences, i.e., combinations in which at least two of the combined sequences are foreign to each other.

[0038] As used herein, the term "non-naturally occurring" when used to refer to an organism means that the organism has at least one genetic change that is not typically found in naturally occurring strains of a reference species (including wild-type strains of the reference species). Genetic changes include, for example, modifications that introduce expressible nucleic acids encoding proteins or enzymes, other nucleic acid additions, nucleic acid deletions, nucleic acid substitutions, or other functional disruptions of the genetic material of the organism. Such modifications include, for example, coding regions of heterologous or homologous polypeptides of the reference species and functional fragments thereof. Additional modifications include, for example, non-coding regulatory regions, where modifications alter the expression of a gene or operon. Genetic modifications to enzyme-encoding nucleic acid molecules or functional fragments thereof can confer biochemical reaction capabilities or metabolic pathway capabilities that are altered from their naturally occurring state on non-naturally occurring organisms.

[0039] As used herein, the term "operably linked" refers to the connection of polynucleotide (or polypeptide) elements in a functional relationship. A nucleic acid is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, if a transcriptional regulatory sequence affects the transcription of a coding sequence, it is operably linked to a coding sequence. Operably linked means that the DNA sequences being linked are typically continuous, and in the case of two protein coding regions, continuous and in reading frame.

[0040] An expression control sequence is "operably linked" to a nucleotide sequence when the expression control sequence controls and regulates the transcription and / or translation of the nucleotide sequence. Thus, an expression control sequence may include a promoter, an enhancer, an internal ribosome entry site (IRES), a transcription terminator, a start codon in front of a protein-coding gene, splicing signals for introns, and a stop codon.

[0041] The term "expression control sequence" is intended to include at least its presence being designed to affect the sequence of expression, and may also include other advantageous components. For example, leader sequences and fusion partner sequences are expression control sequences. The term may also include such a nucleic acid sequence design so that unwanted potential start codons in and out of the frame are removed from the sequence. It may also include such a nucleic acid sequence design so that unwanted potential splicing sites are removed. It includes a sequence or polyadenylation sequence (pA) guiding the addition of a poly A tail, i.e., a string of adenine residues at the 3' end of mRNA, a sequence called a poly A sequence. It may also be designed to enhance mRNA stability. Expression control sequences (e.g., promoters) affecting transcription and translation stability and sequences (e.g., Kozak sequences) affecting translation are known in insect cells. Expression control sequences may have such properties so that the nucleotide sequence operably connected thereto is adjusted so that a lower expression level or a higher expression level is achieved.

[0042] As used herein, the term "codon optimization" refers to an experimental method designed to improve the codon composition of a recombinant gene based on multiple standards without changing the amino acid sequence. This is possible because most amino acids are encoded by more than one codon. Most codon optimization methods avoid using rare codons. However, different methods are different in the degree of other features considered, which include mRNA elements that can suppress expression, nucleotide background of the start codon, mRNA secondary structure, sequence repetition, nucleotide composition, internal ribosome entry site, promoter sequence, and presumed splicing donor and acceptor sites. In addition, some programs consider protein structure information, gene cohesion (A) site, the termination codon in the variable reading frame, and the dinucleotide as the target of RNA enzyme cutting, mutation, and methylation-dependent gene silencing. Those skilled in the art understand the required requirements for designing such codon-optimized nucleic acids.

[0043] DETAILED DESCRIPTION OF THE INVENTION

[0044] The inventors have set out to develop nucleic acids comprising RNA coding sequences to change APOE expression in cells. The human APOE gene is associated with an increased risk of developing AD. In particular, the ε4 variant is involved in late-onset AD (LOAD), and carriers of APOEε4 increase the risk of AD onset in an allele-dependent manner, i.e., one APOEε4 allele advances the age of onset by an average of 2-5 years, while the presence of two APOEε4 alleles advances the onset by 5-10 years. Importantly, 40%-65% of AD patients carry at least one APOEε4 allele. In contrast, APOEε2 and / or APOEε3 alleles play a protective or neutral role in the occurrence of AD. Therefore, reducing RNA expression levels is to reduce neuropathology associated with at least APOE4 expression. Gene therapy methods as outlined herein are used to significantly benefit affected human patients by reversing, preventing neuropathology, slowing the progression of neuropathology, or stopping neuropathology completely.

[0045] In a first aspect of the invention, a nucleic acid is provided, comprising a sequence encoding a first RNA and a sequence encoding a second RNA, wherein the second RNA comprises a guide sequence of at least 19 nucleotides that is substantially complementary to a portion of an APOE gene, and wherein the first RNA and the second RNA each comprise a hairpin.

[0046] RNA

[0047] The term "nucleic acid" as used herein has its conventional meaning in the art. Therefore, the term "RNA" or "RNA molecule" or "ribonucleic acid molecule" as used herein refers to a polymer of ribonucleotides (e.g., 2, 3, 4, 5, 10, 15, 20, 25, 30 or more ribonucleotides), and the term "DNA" or "DNA molecule" or "deoxyribonucleic acid molecule" as used herein refers to a polymer of deoxyribonucleotides. DNA and RNA can be naturally synthesized (e.g., synthesized by DNA replication or DNA transcription, respectively). RNA can be post-transcriptionally modified. DNA and RNA can also be chemically synthesized. DNA and RNA can be single-stranded (i.e., ssRNA and ssDNA, respectively) or multi-stranded (e.g., double-stranded, i.e., dsRNA and dsDNA, respectively). "mRNA" or "messenger RNA" is a single-stranded RNA that specifies the amino acid sequence of one or more polypeptide chains. When ribosomes bind to mRNA, this information is translated during protein synthesis.

[0048] As used herein, the term "small interfering RNA" ("siRNA") (also referred to in the art as "short interfering RNA") refers to an RNA (or RNA analog) that is capable of directing or mediating RNA interference and comprises between about 10-50 nucleotides (or nucleotide analogs). Preferably, the siRNA comprises between about 15-30 nucleotides or nucleotide analogs, more preferably between about 16-25 nucleotides (or nucleotide analogs), even more preferably between about 18-23 nucleotides (or nucleotide analogs) and even more preferably between about 19-22 nucleotides (or nucleotide analogs) (e.g., 19, 20, 21 or 22 nucleotides or nucleotide analogs). The term "short" siRNA refers to an siRNA comprising about 21 nucleotides (or nucleotide analogs) (e.g., 19, 20, 21 or 22 nucleotides). The term "long" siRNA refers to an siRNA comprising about 24-25 nucleotides (e.g., 23, 24, 25 or 26 nucleotides). In some cases, short siRNAs can comprise less than 19 nucleotides (e.g., 16, 17, or 18 nucleotides), provided that the shorter siRNA retains the ability to mediate RNAi. Likewise, in some cases, long siRNAs can comprise more than 26 nucleotides, provided that the longer siRNA retains the ability to mediate RNAi in the absence of further processing (e.g., enzymatic processing) to short siRNAs.

[0049] As used herein, the term "RNA interference" ("RNAi") refers to the selective intracellular degradation of RNA. RNAi is naturally present in cells to remove foreign RNA (e.g., viral RNA). Natural RNAi is carried out via fragments cut from free dsRNA, which direct the degradation mechanism to other similar RNA sequences. Alternatively, RNAi can be induced, for example, to silence the expression of a target gene. Double-stranded RNA structures suitable for inducing RNAi are well known in the art. For example, small interfering RNA (siRNA) can induce RNAi. siRNA comprises two separate RNA chains, one chain comprising a first RNA sequence, and the other chain comprising a second RNA sequence, thus referred to as the first chain and the second chain. Frequently used siRNA designs involve continuous base pairs with 3' overhangs. The first chain and / or the second chain may comprise a 3' overhang. The 3' overhang is preferably a dinucleotide overhang on both chains of the siRNA. Such a design is based on the observed Dicer processing of larger double-stranded RNAs, which produces siRNAs with these characteristics. The 3' overhang may be contained in the first chain. The 3' overhang may be outside the first chain. The two strands comprising the siRNA can be 19, 20, 21, 22, 23, 24, 25, 26, or 27 or more nucleotides in length.

[0050] siRNA can also serve as Dicer substrate. For example, the Dicer substrate can be a 27-mer composed of two RNA chains with 27 continuous base pairs. The first chain is located at the 3' end of the 27-mer duplex. At the 3' end, as with siRNA, each chain or one chain can include two nucleotide overhangs. The 3' overhang can be included in the first chain. The 3' overhang can be outside the first chain. At the 5' end of the first chain, additional sequences that are complementary or non-complementary to the adjacent target RNA sequence can be included. The other end of the siRNA dicer substrate is blunt-ended. This dicer substrate design may lead to a preference for processing by Dicer, so that siRNA can be formed as the siRNA design as described above, with 19 continuous base pairs and 2 nucleotide overhangs at both 3' ends. In any case, siRNA and the like consist of two separate RNA strands (Fire et al. 1998, Nature. 1998 Feb 19;391(6669):806-11), each of which comprises or consists of a first RNA strand and a second RNA strand according to the invention. Thus, it can be said that the nucleic acid of the invention derives a first RNA strand and a second RNA strand (which is the first RNA), as well as a third RNA strand and a fourth RNA strand (which is the second RNA). Alternative naming conventions for each of the first RNA strand, the second RNA strand, the third RNA strand and the fourth RNA strand are within the scope of the invention, and they may be complementary, substantially complementary or unique to each other, or in any other desired arrangement as discussed herein.

[0051] The loop sequence can also be a stem-loop sequence, thereby extending the double-stranded region of the shRNA. As with the siRNAdicer substrate as described above, the shRNA can be processed by, for example, Dicer to provide an siRNA having an siRNA design as described above, with, for example, 19 consecutive base pairs and 2 nucleotide overhangs at both 3' ends. In the case where the shRNA is to be processed by Dicer, it is preferred to have a first strand and a second strand at the end of the shRNA, so that the putative strands of the siRNA are connected via a stem-loop sequence: 5'-first strand-top loop sequence-second strand-optional 2nt overhang sequence-3'. Or conversely, 5'-second strand-top loop sequence-first strand-optional 2nt overhang sequence-3'. Another shRNA design can be an shRNA structure that is processed by the RNAi machinery to provide an activated RISC complex that does not require Dicer processing (Liu et al., Nucleic Acids Res. 2013 Apr 1; ​​41(6):3723-33, incorporated herein by reference), the so-called AgoshRNA or Ago2 processed shRNA, which is based on a structure very similar to the miR-451 scaffold as described below. Such an shRNA structure contains a portion of the first RNA sequence in its loop sequence. Such an shRNA structure can also consist of a first strand followed by a second strand.

[0052] In one embodiment, nucleic acid is provided, wherein the sequence encoding the first RNA is followed by an intron and a sequence encoding the second RNA, wherein the intron is at least 50 nucleotides. Therefore, preferably, in the 5' to 3' direction, the sequence encoding the first RNA is followed by a first intron comprising at least 50 nucleotides, which is followed by a sequence encoding the second RNA. It should be understood that in the case of ds nucleic acids, the 5' to 3' direction refers to the coding strand. It is identified by chance that the sequence encoding the first RNA and the second RNA is processed downstream using an intron as described herein, allowing the combination thereof to be achieved. As described above, it can be said that the nucleic acid derives the first RNA chain and the second RNA chain (which is the first RNA), and the third RNA chain and the fourth RNA chain (which is the second RNA), wherein the sequence encoding the first RNA chain and the second RNA chain is followed by a spacer and a sequence encoding the third RNA chain and the fourth RNA chain, wherein the spacer is at least 50 nucleotides, such as at least 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125 or 130 nucleotides. In some embodiments, the spacer is between 60 and 130 nucleotides. In a preferred embodiment, the spacer is between 90 and 105 nucleotides. In a more preferred embodiment, the spacer is 92 nucleotides. In some embodiments of the present invention, the spacer comprises SEQ ID NO.237. Therefore, when transcribed from physically adjacent genes, the first RNA and the second RNA can also be referred to as RNA clusters. In another embodiment, in the case where one or both RNAs are shRNAs to be processed by Dicer, the above-mentioned related shRNA structures are also applicable. In alternative embodiments, when one or both RNAs are AgoshRNAs, the above-mentioned related shRNA structures are also applicable. Therefore, one or both RNAs can be processed by the same or different RNAi machines (such as Dicer and / or Ago2 of RNAi machines). In a preferred embodiment, the first RNA is processed by Dicer, so the putative strands of the subsequent siRNA are connected via a stem-loop sequence: 5'-first strand-top loop sequence-second strand-optional 2nt overhang sequence-3', or conversely, 5'-second strand-top loop sequence-first strand-optional 2nt overhang sequence-3'. As shown in the examples, the first and second strands of the present invention can preferably be incorporated into a precursor miRNA or pre-miRNA scaffold derived from a pre-miRNA (pri-miRNA) or precursor miRNA (pre-miRNA) scaffold (derived from miR-144 (SEQ ID NO.235)). In a preferred embodiment, the third and fourth strands of the present invention are incorporated into a pre-miRNA or pre-miRNA scaffold derived from miR-451 (SEQ ID NO.190).Thus, the first RNA and / or the second RNA may be described as a hairpin or double-stranded RNA that is substantially complementary to itself. In a more preferred embodiment, the first RNA comprises SEQ ID NO. 235 (miR-144) or a variant thereof.

[0053] In some embodiments of the present invention, the first RNA is incorporated into a precursor miRNA or pre-miRNA scaffold derived from miR-144, and the first RNA is mutated to reduce the processing and / or expression of the first RNA. In some specific embodiments, SEQ ID NO.235 or a variant thereof is mutated to reduce the processing and / or expression of the first RNA. In some embodiments, the mutation is a single point mutation. In other words, the first RNA comprises a single point mutation to reduce the processing and / or expression of the first RNA. In some preferred embodiments, the single point mutation is AT-position 19 (SEQ ID NO.236). The technician can easily determine whether this is the case by using standard assays and appropriate controls (as described in the examples and known in the art).

[0054] Thus, in some embodiments, the first RNA is processed by Dicer and the second RNA is processed by Ago2, such as AgoshRNA or miR-451 mimic RNA, and it can be said that a portion of the second RNA sequence is included in its loop sequence. Such a shRNA structure can also be composed of the third strand of the present invention, followed by the fourth strand.

[0055] Double-stranded RNA according to the present invention can also be incorporated into precursor miRNA or pre-miRNA scaffold. MicroRNA (i.e., miRNA) is a guide strand derived from double-stranded RNA molecules, which are endogenously expressed in mammalian cells, for example. Two or more miRNAs can also be included in miRNA clusters, wherein the miRNAs in the clusters are transcribed in the same direction and are not separated by transcription units or miRNAs in the opposite direction. MiRNA is processed from precursor miRNA precursor molecules, similar to shRNA or extended siRNA processed by RNAi machinery as described above, and is incorporated into activated RNA-induced silencing complexes (RISC) (Tijsterman M, Plasterk RH. Dicers at RISC [Dicer at RISC]; the mechanism of RNAi [RNAi mechanism]. Cell [cell]. April 2, 2004; 1 17 (1): 1-3). Precursor miRNA is a hairpin RNA molecule, which may be part of a larger RNA molecule (pre-miRNA), for example contained in an intron, which is first processed by Drosha to form a pre-miRNA hairpin molecule. In one embodiment, the hairpin in the second RNA comprises at least 40 nucleotides. Precursor miRNA molecules are shRNA-like molecules, which may then be processed by Dicer or Ago2 to produce siRNA-like double-stranded RNA duplexes (see Figure 2 A and Figure 2 B).

[0056] The miRNA (i.e., guide strand) as part of a double-stranded RNA duplex is then incorporated into RISC. In one embodiment, the second RNA comprises a guide sequence of at least 19 nucleotides (e.g., 20, 21, 22, 23, 24, 25, or 26 nucleotides) that are substantially complementary to a portion of the APOE gene. In another embodiment, the second RNA comprises a guide sequence of at least 22 nucleotides that are substantially complementary to a portion of the APOE gene, and preferably the guide sequence is specific to a portion of the APOE4 gene. It was identified by chance that the length of the guide sequence provided as described herein is specific to a portion of the APOE4 gene to achieve the optimal length for the desired effect. Shorter sequences may result in off-target effects. RNA molecules (as present in nature, i.e., pre-miRNA, precursor miRNA, or miRNA duplex) can be used as a scaffold for producing artificial miRNAs that specifically target selected genes. Based on the predicted RNA structure of the RNA molecule as it occurs in nature, e.g. as predicted using, e.g., m-fold software using standard settings (Zuker. Nucleic Acids Res. [Nucleic Acids Research] 31 (13), 3406-3415, 2003), the natural miRNA sequence present in the RNA structure (i.e., duplex, precursor miRNA or pre-miRNA) and the sequence substantially complementary thereto present in the structure are removed and replaced with the first and second strands according to the invention (i.e., the first and second strands of the first RNA or the first and second strands of the second RNA (which may also be referred to as the third and fourth strands)). Thus, the first and second strands are used only for exemplary purposes, and the first and second strands are preferably selected such that the predicted secondary RNA structure formed (i.e., precursor miRNA, pre-miRNA and / or miRNA duplex) is similar to the corresponding predicted original secondary structure of the natural RNA sequence. Precursor miRNA, pre-miRNA and miRNA duplexes (which consist of two separate RNA chains hybridized via complementary base pairing) as found in nature are usually not completely base paired, i.e. not all nucleotides corresponding to the first and second chains as defined above are base paired, and the first and second chains are usually not of the same length. How to use miRNA precursor molecules as scaffolds for any selected target RNA sequence and a substantially complementary first chain is described in, for example, Liu YP Nucleic Acids Res. [Nucleic Acids Research] May 2008; 36 (9): 281 1-24, which is incorporated herein by reference.

[0057] Pre-miRNA can be processed by the RNAi machinery of the cell. Pre-miRNA contains flanking sequences at the 5' end and 3' end of the pre-miRNA hairpin and / or shRNA-like molecule. Such pre-miRNA hairpin can be processed by Drosha to produce pre-miRNA. The length of the flanking sequence can vary, but the length can be about 80nt (Zeng and Cullen, J Biol Chem. [Journal of Biological Chemistry] July 29, 2005; 280 (30): 27595-603; Cullen, Mol Cell. [Molecular Cell] December 22, 2004; 16 (6): 861-5). The minimum length of the single-stranded flank can be easily determined, because when it becomes too short, the RNA molecule may lose its function, because, for example, Drosha processing cannot lead to reduced or even absent sequence-specific inhibition. In one embodiment, the pre-miRNA scaffold carrying the first and second strands according to the present invention has a 5' sequence flank and a 3' sequence flank of at least 5, at least 10, at least 15, at least 20, at least 30, at least 40 or at least 50 nucleotides relative to the predicted pre-miRNA structure. Preferably, the pre-miRNA derived flanking sequences (5' and 3') contained in the miRNA scaffold are derived from the same naturally occurring pre-miRNA sequence. Preferably, the pre-miRNA and / or pre-miRNA derived flanking sequences (5' and 3') and / or loop sequences contained in the miRNA scaffold are derived from the same naturally occurring pre-miRNA sequence. Since the (putative) guide strand RNA as contained in the endogenous miRNA sequence can be replaced by a sequence comprising (or consisting of) the first strand, and the passenger strand sequence can be replaced by a sequence comprising (or consisting of) the second strand, it is understood that the flanking sequences and / or loop sequences of the pre-miRNA or precursor miRNA sequence of the endogenous sequence can contain small sequence modifications such that the predicted structure (e.g., M-fold predicted structure) of the scaffold miRNA sequence is the same as the predicted structure of the endogenous miRNA sequence.

[0058] The first and second strands and the third and fourth strands (such as to form two double-stranded RNAs (i.e., the first RNA and the second RNA of the present invention)) are encoded by an expression cassette. It should be understood that when the double-stranded RNA is, for example, two siRNAs, each siRNA consists of two strands, and two or more expression cassettes may be required. When each double-stranded RNA is contained in a single RNA molecule (e.g., encoding shRNA, precursor miRNA or pre-miRNA), one expression cassette for each RNA molecule may be sufficient. The pol II expression cassette may comprise a promoter sequence (a sequence encoding the RNA to be expressed), followed by a polyadenylation sequence. In the case where the expressed double-stranded RNA comprises a pre-miRNA scaffold, the encoded RNA sequence may encode intron sequences and exon sequences as well as 3'UTR and 5'UTR. The pol III expression cassette typically comprises a promoter sequence, followed by a sequence encoding RNA (e.g., a shRNA sequence, a precursor miRNA, or a strand of a double-stranded RNA to be contained in, for example, an siRNA or a 5T-extended siRNA). The pol I expression cassette may comprise a pol I promoter, followed by an RNA coding sequence and a 3' sequence. Expression cassettes for double-stranded RNA are well known in the art, and any type of expression cassette may suffice, for example, a pol III promoter, a pol II promoter, or a pol I promoter may be used (e.g., (ia), ter Brake et al., Mol Ther. 2008 Mar; 16(3):557-64; Maczuga et al., BMC Biotechnol. 2012 Jul 24; 12:42). In one embodiment, the expression cassette is a DNA molecule. Such DNA molecules may be used for applications in other techniques and applications to provide vectors for nucleic acids as described herein.

[0059] As can be clearly seen from the above, the first and second chains (therefore the third and fourth chains) contained in the double-stranded RNA can contain additional nucleotides and / or nucleotide sequences. Double-stranded RNA can be contained in a single RNA sequence or in two separate RNA chains. No matter what design is used, it is designed so that from the first RNA sequence and the second RNA sequence, the antisense RNA molecule (all or most thereof) comprising the first chain (therefore the third chain) of the present invention can be processed by the RNAi machine so that it is incorporated into the RISC complex to achieve its effect, i.e., to induce RNAi for the RNA target sequence contained in the RNA encoded by the APOE gene. The sequence (all or most thereof) comprising the first chain (therefore the third chain) or consisting of it can sequence-specifically target the RNA encoded by the human APOE gene. Therefore, as long as the double-stranded RNA can induce RNAi, the present invention contemplates such double-stranded RNA. In one embodiment, the double-stranded RNA according to the present invention is contained in a precursor miRNA scaffold, a pre-miRNA scaffold, shRNA or siRNA. Preferably, the first and second chains or the third and fourth chains or all four chains encoded by the expression cassette are contained in a single transcript. It is understood that the expressed transcripts upon subsequent processing (ie, cleavage) results in a single transcript being processed into multiple separate RNA molecules.

[0060] The term complementary is defined herein as the nucleotides of a nucleic acid sequence that can be combined with another nucleic acid sequence by hydrogen bonds, i.e., nucleotides that can base pair. Ribonucleotides (structural units of RNA) are composed of monomers (nucleotides) containing sugar, phosphate and bases, and the bases are purines (guanine, adenine) or pyrimidines (uracil, cytosine). Complementary RNA chains form double-stranded RNA. Double-stranded RNA can be formed by two separate complementary RNA chains, or two complementary RNA chains can be included in one RNA chain. In complementary RNA chains, nucleotides cytosine and guanine (C and G) can form base pairs, and guanine and uracil (G and U) and uracil and adenine (U and A) can also form base pairs. The term substantial complementarity means that it is not necessary to make the first RNA sequence and the second RNA sequence fully complementary, or it is not necessary to make the first RNA sequence and the target RNA sequence or the RNA sequence encoded by the human APOE gene fully complementary.

[0061] Target sequence

[0062] The second RNA to be expressed according to the present invention (all or most thereof) comprises a guide strand, also referred to as an antisense strand, because it is complementary ("anti") to a sense target RNA sequence, which is contained in an RNA encoded by the human APOE gene. Therefore, the second RNA also comprises a "sense strand", which may have substantial sequence identity with the target RNA sequence or be identical to the target RNA sequence. Therefore, the second RNA may be described as a hairpin or double-stranded RNA that is substantially complementary to itself. The double-stranded RNA according to the present invention induces RNA interference, thereby reducing the expression of APOE transcripts, including knocking down APOE-derived transcripts. Transcripts that can be targeted may include spliced ​​(including splice variants) and unspliced ​​RNA transcripts, as encoded by SEQ ID NO.1. Therefore, the RNA encoded by the human APOE gene is understood to include unspliced ​​mRNAs, which include 5' untranslated regions (UTRs), introns and exon sequences, followed by 3'UTRs and poly A tails; and splice variants thereof. The double-stranded RNA according to the present invention may also induce transcriptional silencing. It will be appreciated that according to the invention, rather than providing an expression cassette, the third and fourth strands may be provided which together encode a second RNA.

[0063] In one embodiment, the double-stranded RNA according to the present invention comprises a first RNA sequence and a second RNA sequence (i.e., a third RNA chain and a fourth RNA chain), wherein the first RNA sequence and the second RNA sequence are substantially complementary, and wherein the first RNA sequence has a sequence length of at least 19 nucleotides and is substantially complementary to a target RNA sequence of an RNA encoded by a human APOE gene, and the first RNA sequence is capable of inducing an RNA interference sequence, specifically reducing the expression of an RNA transcript comprising a target RNA sequence. In another embodiment, the induction of RNA interference means that it reduces APOE gene expression to reduce the expression of an RNA transcript comprising a target RNA sequence. As previously discussed, the APOE gene comprises a single nucleotide polymorphism (SNP) that induces differences in the amino acid residues at positions 112 and 158 in the APOE subtype (APOEε2, Cys112 / Cys158; APOEε3, Cys112 / Arg158; APOEε4, Arg112 / Arg158). These single amino acid polymorphisms are believed to seriously affect the structure and function of APOE, thereby affecting Aβ metabolism, aggregation, deposition and tau protein phosphorylation. (Liu et al. 2013, Nat Rev Neurol. [Natural Review Neurology]; 9: 106-18). Small differences between APOE subtypes mean that targeting using RNA sequences as defined herein may result in reduced expression of all APOE, preferably using RNA sequences as defined to target resulting in reduced expression of all APOE. However, in alternative embodiments, a single subtype can be targeted. The design of a single RNA sequence is within the professional knowledge of those skilled in the art. In some embodiments, the target RNA sequence targets a portion of the APOE gene, preferably a portion of the target RNA sequence targeting the APOE4 gene. Therefore, the present invention is intended to reduce the APOEε4 variant involved in late-onset AD (LOAD), because carriers of APOEε4 have an increased risk of AD onset in an allele number-dependent manner. In addition, the present invention is intended to reduce the adverse consequences of development and craniocerebral injury (TBI) associated with APOEε4 variants (APOE4) associated with atherosclerosis. The "reduction" of APOE4 involves the use of a target RNA sequence targeting a portion of the APOE4 gene as described herein. The inventors have identified that the length and target site of the target RNA sequence have the desired results of improving diseases associated with APOE4 expression, as discussed above and shown in the examples.

[0064] Therefore, reducing the expression of APOE transcripts is preferably understood herein as reducing the steady-state level of functional APOE mRNA in target cells, so that less mRNA available in the cell is used for translation into APOE protein, thereby reducing the steady-state level of protein in the target cell. Therefore, reducing the expression of APOE transcripts does not necessarily involve reducing the de novo transcription of the APOE gene, but rather increasing the degradation of APOE mRNA and / or its precursors (e.g., unspliced ​​RNA transcripts).

[0065] By using a standard luciferase reporter assay and appropriate controls, as described in the Examples and known in the art (Zhuang et al. 2006 Methods Mol Biol. [Molecular Biology Methods] 2006; 342: 181-7), the extent of reduction in APOE gene expression can be readily determined, even for individual isoforms. For example, a luciferase reporter comprising a target RNA sequence can be used to show that a double-stranded RNA according to the present invention can be sequence-specifically knocked down. In addition, as shown in, for example, the example section, the level of APOE expression can be determined by detecting APOE RNA (nuclear and / or cytoplasmic) or APOE protein.

[0066] As used herein, the term "RNA silencing" refers to a group of sequence-specific regulatory mechanisms mediated by RNA molecules (e.g., RNA interference (RNAi), transcriptional gene silencing (TGS), post-transcriptional gene silencing (PTGS), suppression, co-repression, and translational repression), which results in the inhibition or "silencing" of the expression of the corresponding protein-coding gene. RNA silencing has been observed in many types of organisms, including plants, animals, and fungi.

[0067] It should be understood that in this context, "substantially complementary" means that all nucleotides of the guide sequence and the target sequence do not need to be base paired (i.e., fully complementary), or all nucleotides of the guide sequence and the target sequence do not need to be base paired. Such substantial complementarity is contemplated according to the present invention as long as the second RNA is capable of inducing RNA interference to sequence-specifically target a sequence comprising the target RNA sequence.

[0068] The substantial complementarity between the chain complementary to the target RNA sequence (also referred to as a part of the APOE gene) is preferably composed of at most two mismatched nucleotides, more preferably with one mismatched nucleotide, and most preferably without mismatches. It should be understood that a mismatched nucleotide means that when base-pairing with the target RNA sequence, one nucleotide does not base-pair with the target RNA sequence over the entire length of the chain complementary to the target RNA sequence. No mismatch means that all nucleotides of the chain complementary to the target RNA base-pair with the target RNA sequence, and having 2 mismatches means that two nucleotides of the chain complementary to the target RNA do not base-pair with the target RNA sequence. The chain complementary to the target RNA can also include additional nucleotides that do not have complementarity with the target RNA sequence, and can be longer than, for example, 21 nucleotides, in which case substantial complementarity is determined over the entire length of the target RNA sequence. This means that in this embodiment, when base-pairing with the chain complementary to the target RNA, the target RNA sequence has no mismatch, one mismatch or two mismatches over its entire length.

[0069] As shown in the example section, a double-stranded RNA comprising a chain complementary to a target RNA of 22 nucleotides in length was tested. These chains complementary to the target RNA have no mispairing, and are fully complementary to the target RNA sequence. However, according to the present invention, it is allowed to have some mispairings between the chain complementary to the target RNA and the target RNA sequence, as long as the double-stranded RNA according to the present invention can reduce the expression of the transcript (such as luciferase reporter or for example the transcript comprising the target RNA sequence) comprising the target RNA sequence. In this embodiment, the substantial complementarity between the chain complementary to the target RNA and the target RNA sequence is composed of the following: there is no mispairing, one mispairing or two mispairings on the entire length of the target RNA sequence encoded by the RNA of the target RNA or by the RNA of people APOE, whichever is the shortest.

[0070] As described, mismatch according to the present invention means that the nucleotides of the first or third strands are not base-paired with the target RNA sequence encoded by the RNA of human APOE. The nucleotides that are not base-paired are A and A, G and G, C and C, U and U, A and C, C and U or A and G. Mismatch may also be caused by the deletion of nucleotides or the insertion of nucleotides. When the mismatch is a deletion in the first or third strand sequence, this means that when compared with the entire length of the first or third strand sequence, the nucleotides of the target RNA sequence are not base-paired with the first or third strand sequence. The nucleotides that can be base-paired are AU, GC and GU. GU base pairs are also referred to as GU wobble or wobble base pairs. In one embodiment, the number of GU base pairs between the first or third strand sequence and the target RNA sequence is 0, 1 or 2. In one embodiment, there is no mismatch between the first or third strand sequence and the target RNA sequence, and one GU base pair or multiple GU pairs are allowed. Preferably, there may be no GU base pair between the first or third strand sequence and the target RNA sequence, or the first or third strand sequence and the target RNA sequence only have base pairs as AU or GC. Preferably, there is no GU base pair and no mismatch between the first or third strand sequence and the target RNA sequence. The first or third strand sequence of the double-stranded RNA according to the present invention is preferably fully complementary to the target RNA sequence, and the complementarity is composed of GU, GC and AU base pairs. The first or third strand sequence of the double-stranded RNA according to the present invention is more preferably fully complementary to the target RNA sequence, and the complementarity is composed of GC and AU base pairs. More preferably, it is the third strand, i.e. the first strand of the second RNA of the present invention.

[0071] Therefore, in one embodiment, the first strand of the second RNA and the target RNA sequence have at least 15, 16, 17, 18 or 19 nucleotides of base pairing. Preferably, the first strand of the second RNA and the target RNA sequence are substantially complementary, and the complementarity comprises at least 19 base pairs. In another embodiment, the first strand of the second RNA has at least 8, 9, 10, 11, 12, 13 or 14 continuous nucleotides of continuous nucleotide base pairing with the target RNA sequence. In another embodiment, the first strand of the second RNA has at least 19 continuous nucleotides of continuous nucleotide base pairing with the target RNA sequence. In another embodiment, the first strand of the second RNA comprises at least 19 continuous nucleotides of 19 continuous nucleotide base pairing with the target RNA sequence. In still another embodiment, the first strand of the second RNA has at least 17 nucleotides of base pairing with the target RNA sequence, and has at least 15 continuous nucleotides of continuous nucleotide base pairing with the target RNA sequence. The sequence length of the first strand is preferably at most 21, 22, 23, 24, 25, 26 or 27 nucleotides. In another embodiment, the first strand of the second RNA has at least 20 consecutive nucleotides that are base-paired with 20 consecutive nucleotides of the target RNA sequence. In another embodiment, the first strand of the second RNA comprises at least 21 consecutive nucleotides that are base-paired with 21 consecutive nucleotides of the target RNA sequence.

[0072] As described, it may not be necessary to have complete complementarity (that is, complete base pairing (no mispairing) and no GU base pair) between the first chain of the second RNA and the target RNA sequence, because such a first chain of the second RNA can still allow sufficient suppression of gene expression. In addition, it can be considered that there is no complete complementarity, for example, to avoid or reduce the specific gene suppression of the RNA sequence of the target RNA sequence, while maintaining the sequence-specific suppression of the transcript comprising the target RNA sequence. However, it may be preferred to have complete complementarity, because it may lead to more effective suppression. Not bound by theory, the first chain of the second RNA and the target RNA sequence have complete complementarity between them, which can allow the activated RISC complex of the first chain (or most of it) comprising the second RNA to cut its target RNA sequence, and have mispairing that may hinder cutting and may cause mainly to allow inhibition of translation, wherein the latter may cause the inhibition of efficacy to weaken.

[0073] About the second strand on the second RNA, the second strand is substantially complementary to the first strand. The second strand combined with the first strand forms a double-stranded RNA. As described, this forms a suitable substrate for RNA interference machinery, so that the guide sequence derived from the first strand is included in the RISC complex, so that sequence-specific inhibition of its target (i.e., RNA encoded by the human APOE gene) expression. The sequence of the second strand has sequence similarity with the target RNA sequence. However, the substantial complementarity of the second strand to the first strand can be selected to have less substantial complementarity compared with the substantial complementarity between the first strand and the target RNA sequence. Therefore, the second strand can include 0, 1, 2, 3, 4 or more mismatches, 0, 1, 2, 3 or more GU wobble base pairs, and can include the insertion of 0, 1, 2, 3, 4 nucleotides and / or the deletion of 0, 1, 2, 3, 4 nucleotides. Preferably, the first strand and the second strand are substantially complementary, and the complementarity includes 0, 1, 2 or 3 GU base pairs and / or wherein the complementarity includes at least 17 base pairs. These mismatches, GU wobble base pairs, insertions and deletions are about the first strand (i.e., the double-stranded region formed between the first strand and the second strand). As long as the first strand and the second strand can be substantially base-paired and can induce sequence-specific inhibition of the RNA encoded by the human APOE gene, such substantial complementarity is allowed according to the present invention. It should also be understood that the substantial complementarity between the first strand and the second strand may depend on the selected double-stranded RNA design. It may depend, for example, on the selected miRNA scaffold in which the double-stranded RNA is to be incorporated.

[0074] As can be clearly seen from the above, the substantial complementarity between the first and second strands of the second RNA can include mismatches, deletions and / or insertions relative to the first RNA sequence and the second RNA sequence that are fully complementary (i.e., fully base paired). In one embodiment, the first and second strands of the second RNA have at least 11 continuous base pairs. Therefore, at least 11 continuous nucleotides of the first strand and at least 11 continuous nucleotides of the second strand are fully complementary. In another embodiment, the first and second strands of the second RNA have at least 15 nucleotides of base pairing. The base pairing between at least 15 nucleotides of the first strand and at least 15 nucleotides of the second strand can be composed of GU, GC and AU base pairs, or can be composed of GC and AU base pairs. In another embodiment, the first RNA sequence and the second RNA sequence have at least 15 nucleotides of base pairing, and have at least 11 continuous base pairs. In another embodiment, the first RNA sequence and the second RNA sequence are substantially complementary, wherein the complementarity comprises at least 17 base pairs. The 17 base pairs may preferably be 17 consecutive base pairs, and the base pairing consists of GU, GC and AU base pairs, or consists of GC and AU base pairs.

[0075] As described, the present invention now provides an expression cassette encoding a first and second strand of a second RNA, wherein the first and second strands are substantially complementary, wherein the first strand has a sequence length of at least 19 nucleotides, and is substantially complementary to a target RNA sequence contained in an RNA encoded by a human APOE gene. As shown in the examples, suitable target RNA sequences according to the present invention are provided (see, e.g., Table 1). Therefore, in one embodiment, an expression cassette encoding a first and second strand is provided, wherein the first and second strands are substantially complementary, wherein the first strand has a sequence length of at least 19 nucleotides, 20 nucleotides, 21 nucleotides, or 22 nucleotides, and is substantially complementary to a target RNA sequence selected from the RNA encoded by a human APOE gene listed in Table 1.

[0076] Table 1: RNA target sequences encoded by the human APOE gene.

[0077]

[0078]

[0079]

[0080]

[0081] Table 1. SEQ ID NO.2-93 corresponds to the target RNA sequence of the transcript encoded by the human APOE gene. For these target RNA sequences, it is found that the unexpectedly highly advantageous suitable third and fourth chains of the second RNA can be prepared according to the present invention to provide an expression cassette encoding the second RNA, wherein the third and fourth chains are substantially complementary, wherein the third strand RNA sequence has a sequence length of at least 19 nucleotides and is substantially complementary to one of the target RNA sequences to efficiently induce RNAi to reduce APOE gene expression. It should be understood that the reduction of APOE gene expression can include a reduction in transcripts associated with tau protein disease.

[0082] As shown in the examples, the third and fourth chains of the present invention can preferably be incorporated into a pre-miRNA or pre-miRNA scaffold derived from miR-101 or a pre-miRNA or pre-miRNA scaffold derived from miR-451. In a preferred embodiment, the third and fourth chains of the present invention are incorporated into a pre-miRNA or pre-miRNA scaffold derived from miR-451. These scaffolds are found to be particularly useful because they can both induce RNA interference and be combined in a single transcript. These scaffolds also allow for the induction of RNA interference, which may primarily result in RNA interference induced by the guide strand. The pre-miR451 scaffold does not produce a passenger strand because the processing is different from the typical miRNA processing pathway (Cheloufi et al., June 3, 2010; 465(7298):584-9 and Yang et al., Proc Natl Acad Sci USA. [Proceedings of the National Academy of Sciences of the United States] August 24, 2010; 107(34):15163-8). The pre-miR-101 scaffolds are produced by the canonical miRNA processing pathway, but many miR-101 scaffolds were found to produce primarily guide strands (see, e.g., C2, C4, C32, and C33) and very small amounts of passenger strands. Therefore, these two scaffolds represent excellent candidates for developing gene therapy products because the unwanted potential off-targets of the passenger strand can be largely (if not completely) avoided. Since the passenger strand (corresponding to the second sequence) may result in targeting transcripts other than APOE RNA, the use of such scaffolds may allow such unwanted targeting to be avoided. Therefore, it is preferred to select scaffolds that produce less than 15%, less than 10%, less than 5%, less than 4%, or less than 3% of passenger strands. In some embodiments, the second RNA is derived from a pre-miRNA scaffold selected from the group consisting of: pre-miR-21, pre-miR-22, pre-miR-26a, pre-miR-30a, pre-miR-33, pre-miR-122, pre-miR-375, pre-miR-199, pre-miR-99, pre-miR-194, pre-miR-155 and pre-miR-451. In a preferred embodiment, the second RNA is derived from a scaffold comprising SEQ ID NO.190 (miR-451) or a variant thereof. Therefore, in one embodiment, the first RNA comprises SEQ ID NO.235 (miR-144) or a variant thereof, and the second RNA comprises SEQ ID NO.190 (miR-451) or a variant thereof. The experimental data attached hereto support the surprising discovery that when the miRNA cluster method is applied, the improved silencing of APOE is achieved. The specific combination of 144 / 451 scaffolds in the nucleic acid of the present invention is particularly useful in the context of gene therapy and RNA silencing.MiR-144 and miR-451 are examples of clustered miRNAs regulated in trans, wherein miR-144 regulates the processing of miR-451 by Ago2. Specifically, miR-144 trans-enhances miR-451 biogenesis by repressing Dicer and then repressing global typical miRNA processing (Kretov et al., 2020, Molecular Cell [Molecular Cell] 78, 317-328). Although it has been shown that miR451 is the most abundant miRNA in erythrocytes, and clusters with miR144, wherein this cluster plays a complex role during erythropoiesis, the inventors have further developed this cluster and now show for the first time that these miRNAs can also be used as the scaffold of target RNA, which affects their expression when clustered in a similar manner. Therefore, in the case of using this scaffold combination, the first RNA of the present invention plays a key role in enhancing the biogenesis of the second RNA of the present invention and thus enhancing the delivery of the guide sequence contained in the first RNA and the second RNA. Thus, in one embodiment, when the second RNA is expressed with the first RNA, the reduction and / or silencing of APOE expression is increased when compared to the reduction in APOE expression achieved by expressing the second RNA alone.

[0083] As shown in the examples, the first strand of the second RNA of 22 nucleotides in length (e.g., for miR-451) or the third strand of the present invention can be selected and incorporated into the miRNA scaffold. Such miRNA scaffold sequences are subsequently processed by RNAi machinery as present in cells. When referring to miRNA scaffolds, it should be understood to include pre-miRNA structures or precursor miRNA structures. As shown in the examples, when processed in cells, such miRNA scaffolds produce guide sequences, which include the first strand of the second RNA or most of it, for miR-451 scaffolds, in the range of 21-30 nucleotides in length. Such guide chains can reduce APOE transcript expression by targeting the selected target sequence. As can be clearly seen from the above, and as shown in the examples, when the first strand of the second RNA has been processed by the RNAi machinery of the cell, when it is encoded by the expression cassette of the present invention, it is partially or entirely included in the guide chain. Therefore, the guide chain of the first strand of the second RNA and the second strand of the second RNA to be generated from the RNA encoded by the expression cassette includes at least 18 nucleotides of the first RNA sequence. Preferably, such a guide strand comprises at least 19 nucleotides, 20 nucleotides, 21 nucleotides or 22 nucleotides. The guide strand may also comprise the first strand of the second RNA sequence in its entirety. When selecting a miRNA scaffold, the first strand of the second RNA sequence may be selected so that it replaces the original guide strand. As shown in the Examples section, this does not necessarily mean that the guide strand produced by such an artificial scaffold is the same length as the first strand of the selected second RNA, nor does it mean that the first strand of the second RNA is found in its entirety in the produced guide strand. As shown in the Examples, and as Figure 2 As shown in a, the miR-451 scaffold preferably includes, from 5' to 3', first 5'-CUUGGGAAUGGCAAGG-3' (SEQ ID NO.233); followed by a sequence of 22 nucleotides, which comprises or consists of a first RNA sequence; followed by a sequence of 17 nucleotides, which can be considered as a second RNA sequence, which is complementary to nucleotides 2-18 of the 22-nucleotide sequence over its entire length; followed by the sequence 5'-MWCUUGCUAUACCCAGA-3' (wherein M is A or C and W is A or U) (SEQ ID NO.234). Preferably, the first 5'C nucleotide of the latter sequence does not base pair with the first nucleotide of the first strand of the second RNA. Such a scaffold may include additional flanking sequences, as found in the original pre-miR-451 scaffold. Alternatively, the flanking sequences 5'-CUUGGGAAUGGCAAGG'-3' and 5'-MWCUUGCUAUACCCAGA-3' may be replaced by flanking sequences of other pre-mRNA structures. As is clear from the above, the sequence of the scaffold may not only be related to that in the wild-type scaffold ( Figure 2 a) and its complementary sequence present in, and may also comprise additional mutations in the 5', loop and 3' sequences, as additional mutations may be required to provide an RNA structure predicted to mimic the secondary structure of the wild-type scaffold. Such a scaffold may be contained in a larger RNA transcript (e.g., a pol II expressed transcript) comprising, for example, a 5'UTR and a 3'UTR and poly A. Flanking structures may also be absent. Thus, the expression cassette according to the invention expresses an shRNA-like structure having a 22-nucleotide sequence comprising or consisting of a first strand of a second RNA; followed by a 17-nucleotide sequence which may be considered as a second strand of the second RNA, which is complementary to nucleotides 2-18 of said 22-nucleotide sequence over its entire length. The latter shRNA-like structure derived from the miR-451 scaffold may be referred to as a precursor miRNA scaffold from miR-451.

[0084] Alternatively, the flanking sequence can be replaced by the flanking sequence of other precursor miRNA structures. The flanking structure may not exist. Therefore, the expression cassette according to the present invention expresses an shRNA-like structure (precursor miRNA structure of miR-101). Such an shRNA-like structure consists of: a second RNA sequence of 22 nucleotides in length starting from the 5' end; followed by a loop sequence, wherein the last 3' two nucleotides of the loop sequence are base-paired with the last 3' nucleotides of the second strand of the second RNA; followed by the first strand of the second RNA of 21 nucleotides in length, wherein the first 20 continuous nucleotides are complementary to the second strand of the second RNA. The second strand of the second RNA comprises a bulge (non-base-paired nucleotide) at position 5 (counting from the 3' end) of the 22 nucleotides.

[0085] In one embodiment, an expression cassette according to the present invention is provided, wherein the first strand of the second RNA is substantially complementary to a target RNA sequence contained in an antisense RNA transcript encoded by a human APOE gene. Preferably, the first strand of the second RNA is substantially complementary to SEQ ID NO.4, 16, 24, 41, 44, 46, 54, 59, 93. More preferably, the first strand of the second RNA has a length of 19, 20, 21 or 22 nucleotides. More preferably, the first strand of the second RNA is completely complementary to the target sequence over its entire length. Most preferably, the first strand of the second RNA has a length of 19, 20, 21 or 22 nucleotides, wherein the first strand of the second RNA is completely complementary to the target sequence over its entire length. The first strand of the second RNA can be SEQ ID NO.94-185, Table 2.

[0086] Table 2: miAPOE guide strand sequences.

[0087]

[0088]

[0089]

[0090]

[0091] As described, such a first strand of the second RNA is combined with the second strand of the second RNA, and the first strand and the second strand may also be referred to as the third strand and the fourth strand of the present invention. As described herein, the technician can design and select the appropriate second strand of the second RNA so as to provide the first strand and the second strand of the second RNA that can induce RNA interference when expressed in a cell. The appropriate second strand of the second RNA is complementary to nucleotides 2-15, 2-16, 2-17 or 2-18 of the first strand of a second RNA having a length of 19, 20, 21 or 22 nucleotides over its entire length.

[0092] The first strand of the second RNA is preferably comprised in a miRNA scaffold, more preferably a miR-451 scaffold, as shown in the examples. A suitable scaffold comprising the first and second strands of the second RNA according to the invention may be a sequence such as SEQ ID NO.190.

[0093] Such a first strand of the second RNA as described above may be comprised in an expression cassette.Such a first strand of the second RNA may be comprised in an RNA structure encoded by an expression cassette.

[0094] Such first and second chains of the second RNA sequence as described above can be included in an expression cassette. Such first and second chains of the second RNA can be included in an RNA structure encoded by an expression cassette. Therefore, in some embodiments, the sequence encoding the first RNA and the sequence encoding the second RNA are included in an intron sequence. By incorporating the sequence encoding the first RNA sequence and the second RNA sequence, the inventors have identified the beneficial effects of deriving a smaller construct for expressing RNA of the present invention, which is particularly useful for downstream processing steps (such as in the application of viral vector technology). In other embodiments, the sequence encoding the first RNA and the sequence encoding the second RNA are present in a promoter, wherein preferably the intron sequence has SEQ ID NO.231.

[0095] Therefore, it is found that targeting these target RNA sequences using such first and second chains of the second RNA is particularly useful for reducing the expression of RNA transcripts encoded by the human APOE gene. By targeting human APOE in this way, the inventors can efficiently reduce human APOE gene expression, and therefore can reduce the formation of amyloid plaques. Ultimately, this can reverse, prevent neuropathology (such as neurodegeneration and / or tau disease), slow down the progression of neuropathology, or stop neuropathology completely.

[0096] APOE expression

[0097] In a further aspect, an expression cassette encoding at least one of APOE2 and APOE3 is provided. APOEε2 and / or APOEε3 alleles play a protective or neutral role in the occurrence of AD (Yamazaki et al. 2016, CNS Drugs [CNS Drugs].; 30: 773-89). Therefore, in some embodiments, the expression cassette comprises a nucleic acid encoding at least one of APOE2 and APOE3 having an amino acid sequence selected from SEQ ID NO.249-254. The expression of at least one of APOE2 and APOE3 is neuroprotective for tauopathy. The term "tauopathy" as used herein describes a neurodegenerative disorder characterized by the deposition of abnormal tau protein in the brain. In an embodiment, the expression cassette encoding at least one of APOE2 and APOE3 further comprises a promoter and a poly A signal. In further embodiments, the expression cassette comprises a nucleic acid encoding one or more APOE2 and APOE3 proteins having an amino acid sequence selected from one or more of SEQ ID NOs. 249-254 or variants thereof for use in gene therapy.

[0098] In some embodiments, the expression cassette comprises one or more nucleic acid sequences comprising at least part of the wild-type sequence. At least part of the wild-type sequence means a sequence with codon optimization only in a specific region, as can be seen in SEQ ID NO: 212-217. In a preferred embodiment, the expression cassette comprises one or more nucleic acid sequences comprising a full-length wild-type coding sequence (e.g., SEQ ID NO: 195-201). The present invention of the present application has unexpectedly shown that (at least part of) the wild-type form of the nucleic acid sequence shows the highest protein expression in different variants. In a more preferred embodiment, the expression cassette comprises a nucleic acid selected from one of SEQ ID NO.195, 197, 200. In a still more preferred embodiment, the expression cassette comprises a nucleic acid containing SEQ ID NO.197 and 200, because of the known beneficial properties of the encoded protein. In an alternative embodiment, the expression cassette comprises a nucleic acid selected from one of SEQ ID NO.197 and 200. The inventors have unexpectedly shown that the wild-type form of the nucleic acid sequence encoding APOE2 or APOE3 protein is the one that causes the highest protein expression and secretion in different variants. Codon optimization of the full length of the nucleic acid sequence results in reduced expression levels of APOE2 or APOE3 protein.

[0099] In further embodiments, the expression cassette encoding at least one of APOE2 and APOE3 comprises one or more nucleic acid sequences selected from one or more of SEQ ID NOs 195-217 or variants thereof. For example, in still further embodiments, the expression cassette encoding at least one of APOE2 and APO3 comprises 2, or 3, or 4 or more nucleic acid sequences selected from one or more of SEQ ID NOs. 195-217 or variants thereof. In further aspects, an expression cassette as disclosed herein is provided, the expression cassette comprising a nucleic acid comprising a sequence encoding a first RNA as disclosed herein and a sequence encoding a second RNA, wherein the second RNA comprises a guide sequence of at least 19 nucleotides substantially complementary to a portion of the APOE gene, and wherein the first RNA and the second RNA each comprise a hairpin; the expression cassette further comprises a second nucleic acid encoding at least one of APOE2 and APOE3. In embodiments, the first nucleic acid and the second nucleic acid are operably linked to a promoter and a poly A signal. In further embodiments, the second nucleic acid encodes a protein comprising one of SEQ ID NOs 249-254 and / or the second nucleic acid comprises one of SEQ ID NOs. 195-217. Therefore, in some embodiments, the second nucleic acid encodes a protein having an amino acid sequence shown in SEQ ID NO.249-254. In some embodiments, the second nucleic acid is a gene product encoded by a coding portion (e.g., cDNA) of a naturally occurring gene. In some embodiments, the gene product is a protein or fragment thereof encoded by the APOE2 and / or APOE3 subtypes of the APOE gene. In further embodiments, the second nucleic acid does not comprise a sequence substantially complementary to a guide sequence as defined herein. In further embodiments, the second nucleic acid comprises a nucleotide sequence codon-optimized for expression in human cells. In further embodiments, the second nucleic acid is codon-optimized to be sufficiently different from the endogenous APOE2 and / or APOE3 sequences in the cell so that it will not be recognized by the shRNA targeting wild-type APOE, APOE2 and / or APOE3. Those skilled in the art understand the requirements required for designing such nucleic acids. In further embodiments, the second nucleic acid comprises a sequence selected from Table 3 (SEQ ID NO.195-217).

[0100] Table 3. Nucleic acids expressing APOE2 or APOE3.

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116]

[0117] As is known in the art, expression of gene products requires the presence of expression control and / or regulatory sequences, such as one or more promoters and any other nucleic acid sequences necessary for expression of the selected nucleic acid sequence, such as introns, all operably linked to the selected sequence, and may include enhancer sequences. Thus, in one embodiment, an expression construct comprising an expression cassette encoding at least one of APOE2 and APOE3 comprises a promoter. In an alternative embodiment, an expression cassette as disclosed herein comprises a nucleic acid comprising a sequence encoding a first RNA as disclosed herein and a sequence encoding a second RNA, wherein the second RNA comprises a guide sequence of at least 19 nucleotides substantially complementary to a portion of the APOE gene, and wherein the first RNA and the second RNA each comprise a hairpin; the expression cassette further comprises a second nucleic acid encoding at least one of APOE2 and APOE3, and comprises one or more promoters, preferably one promoter. Considering the ability of post-downstream processing associated with transfection and expression, the inventors identified such a design as advantageous.

[0118] Promoter

[0119] The nucleotide sequence comprising one or more expression cassettes for expression in mammalian cells as defined above further preferably comprises at least one mammalian cell compatible expression control sequence (e.g., a promoter) operably linked to a sequence encoding a target gene product, thereby forming an expression cassette for expressing the target gene product in a mammalian target cell to be treated by gene therapy with the target gene product. Many such promoters are known in the art (see Sambrook and Russel, 2001, supra). Constitutive promoters widely expressed in many cell types, such as the CMV promoter, can be used. However, more preferred will be promoters that are inducible, tissue-specific, cell type-specific, or cell cycle-specific. Preferably, a pol II promoter is used, such as the CAG promoter (SEQ ID NO.191) (e.g., Miyazaki et al. Gene [gene]. 79 (2): 269-77; Niwa, Gene [gene]. 108 (2): 193-9), a PGK promoter, a CMV promoter (e.g., in WO 2016102664) Figure 2 , which are incorporated herein by reference) or adapted / synthetic promoters (P1, SEQ ID NO. 192 and P2, SEQ ID NO. 193). Since Alzheimer's disease primarily affects the brain, the use of neural-specific promoters may be particularly useful. Therefore, in some embodiments, the promoter is a promoter capable of driving transcription in brain cells. Examples of suitable neural-specific promoters are neuron-specific enolase (NSE), human synapsin 1, caMK kinase, and tubulin promoters (Hioki et al. Gene Ther. 2007 Jun; 14(11): 872-82). Other suitable promoters that may be considered are inducible promoters, i.e., promoters that initiate transcription only when the host cell is exposed to some specific stimulus.

[0120] As described above, the expression cassette for expressing at least APOE further preferably encodes a poly A signal contained in a DNA expression cassette operably linked to the 3' end of the RNA molecule encoded by the transgene, as described above. Preferably, the poly A signal is a simian virus 40 polyadenylation signal (SV40 poly A, SEQ ID NO. 194), a synthetic polyadenylation signal, a bovine growth hormone polyadenylation signal (BGH poly A) or a human growth hormone polyadenylation signal (HGH poly A).

[0121] Carrier

[0122] The isolated nucleic acid as described herein can exist alone, as part of an expression cassette and / or as part of a vector. Typically, the vector can be a plasmid, a cosmid, a phagemid, a bacterial artificial chromosome (BAC) or a viral vector (such as a gene therapy vector). The expression cassette or vector according to the present invention can be transferred to a cell using, for example, a transfection method. Any suitable means may be sufficient to transfer the expression cassette according to the present invention. Preferably, a viral vector is used to stably transfer the expression cassette to the cell, so that the stable expression of double-stranded RNA for sequence-specific inhibition of the APOE gene as described above can be achieved. Suitable vectors can be lentiviral vectors, retrotransposon-based vector systems or AAV vectors. It should be understood that, since, for example, lentiviral vectors carry an RNA genome, the RNA genome will encode the expression cassette so that after transduction of the cell, the DNA sequence and the expression cassette are formed. Preferably, a viral vector, such as AAV, is used. Therefore, in some embodiments, the expression cassette as disclosed herein is flanked by reverse terminal repeats. Preferably, the AAV vector used is an AAV vector of serotype 5. AAV of serotype 5 (also referred to as AAV5) may be particularly useful for transducing human neurons and human astrocytes, as shown in the Examples. Thus, in some embodiments, there is an AAV comprising an expression cassette as disclosed herein. Thus, AAV5 can effectively transduce different human cell types of the CNS, including FBN, dopaminergic neurons, motor neurons, and astrocytes, and is therefore a suitable vector candidate for delivering therapeutic genes to the CNS to treat neurodegenerative diseases (including but not limited to, treating Alzheimer's disease via targeting, for example, APOE as described herein). The production of AAV vectors comprising any expression cassette of interest is fully described in the following patents: WO 2007 / 046703, WO 2007 / 148971, WO 2009 / 014445, WO 2009 / 104964, WO 2011 / 122950, ​​WO 2013 / 036118, which are incorporated herein in their entirety.

[0123] AAV sequences that can be used in the present invention to generate AAV vectors (e.g., produced in insect or mammalian cell lines) can be derived from the genome of any AAV serotype. In general, AAV serotypes have genome sequences that are significantly homologous at the amino acid and nucleic acid levels, provide the same set of genetic functions, produce substantially physically and functionally equivalent virions, and replicate and assemble by virtually the same mechanisms. For an overview of the genomic sequences and genomic similarities of various AAV serotypes, see, e.g., GenBank Accession No. U89790; GenBank Accession No. J01901; GenBank Accession No. AF043303; GenBank Accession No. AF085716; Chlorini et al. (1997, J. Vir. [J. Virology] 71:6823-33); Srivastava et al. (1983, J. Vir. [J. Virology] 45:555-64); Chlorini et al. (1999, J. Vir. [J. Virology] 73:1309-1319); Rutledge et al. (1998, J. Vir. [J. Virology] 72:309-319); and Wu et al. (2000, J. Vir. [J. Virology] 74:8635-47). AAV serotypes 1, 2, 3, 4 and 5 are preferred sources of AAV nucleotide sequences for use in the context of the present invention. Preferably, the AAVITR sequences for use in the context of the present invention are derived from AAV1, AAV2 and / or AAV5. Similarly, the Rep52, Rep40, Rep78 and / or Rep68 coding sequences are preferably derived from AAV1, AAV2 and AAV5. However, the sequences encoding VP1, VP2 and VP3 capsid proteins for use in the context of the present invention can be taken from any of the known 42 serotypes, more preferably from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 or AAV9 or newly developed AAV-like particles obtained by, for example, capsid shuffling technology and AAV capsid libraries. The AAV capsid can consist of VP1, VP2 and VP3, but can also consist of VP1 and VP3. In some embodiments, the AAV vector according to the present invention comprises AAV5 or AAV9 capsid proteins. In some embodiments, the AAV vector according to the invention comprises an AAV5 capsid protein. In some embodiments, the AAV vector according to the invention comprises an AAV9 capsid protein.

[0124] In another embodiment, a host cell comprising the nucleic acid or the expression cassette according to the invention is provided. For example, the expression cassette or nucleic acid can be contained in a plasmid contained in bacteria. The expression cassette or nucleic acid can also be contained in a production cell that produces, for example, a viral vector. The expression cassette can also be provided in a baculovirus vector.

[0125] Various modifications of the nucleotide sequences as defined above (including, for example, wild-type AAV sequences) for proper expression in host cells are achieved by applying well-known genetic engineering techniques, as described, for example, in Sambrook and Russell (2001) "Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York. Various additional modifications of the coding regions are known to the skilled artisan which may increase the production of the encoded protein. Such modifications are within the scope of the present invention.

[0126] In one embodiment, any mammalian cell can be infected by the AAV vector of the present invention, such as but not limited to muscle cells, hepatocytes, neural cells, glial cells and epithelial cells. In a preferred embodiment, the cells to be infected are human cells.

[0127] It should be understood that the capsid amino acid sequence and the nucleotide sequence encoding them can be engineered, for example, the sequence can be a heterozygous form or can be codon optimized, such as by the codon usage of AcmNPv or fall armyworm. Capsid protein can be engineered, for example, via DNA shuffling, error-prone PCR, bioinformatics rational design or site saturation mutagenesis. The resulting capsid is based on existing serotypes, but contains a variety of amino acids or nucleotide changes that improve the characteristics of such capsids. The resulting capsid can be a combination of different parts of an existing serotype, a "shuffled capsid", or contains completely novel changes, i.e., the addition, deletion or replacement of one or more amino acids or nucleotides, to be organized in groups or distributed over the entire length of a gene or protein. See, e.g., Schaffer and Maheshri; Proceedings of the 26th Annual International Conference of the IEEE EMBS San Francisco, CA, USA; September 1-5, 2004, pp. 3520-3523; Asuri et al., 2012, Molecular Therapy 20(2):329-3389; Lisowski et al., 2014, Nature 506(7488):382-386, incorporated herein by reference.

[0128] In some embodiments, the ITR and capsid protein (or portion thereof) in the AAV vector of the invention may be from different AAV serotypes. By way of example and not limitation, the ITR may be derived from AAV2, while the capsid protein may be derived from a different serotype, such as AAV5 or AAV9.

[0129] Composition

[0130] On the other hand, the present invention relates to a pharmaceutical composition comprising an AAV vector according to the present invention, i.e., an AAV vector comprising a nucleic acid according to the present invention or an AAV vector according to the present invention. In one embodiment, the present invention provides a composition comprising an AAV vector according to the present invention and a suitable excipient (such as a buffer and a stabilizer, an antioxidant, etc.). In a specific embodiment, these compositions are used to transduce cells in vitro or ex vivo, in which case the excipient will need to be compatible with the cell culture. In other preferred embodiments, the composition is used to treat (human) subjects. For this purpose, the present invention provides a pharmaceutical composition comprising an AAV vector according to the present invention and at least one pharmaceutically acceptable carrier. In the case of an AAV gene delivery vehicle, the pharmaceutical composition typically comprises a physiological buffer (such as PBS), which comprises an additional stabilizer, such as sucrose. Such compositions are compatible with subsequent intravenous, intrathecal, intraparenchymal, intravitreal, subretinal administration of organ-targeted vascular delivery (such as intraporal or intracoronary delivery or isolated limb perfusion), and are suitable for and intended to be used therein. Therefore, in some embodiments, the present invention provides a nucleic acid according to the present invention, or an expression cassette according to the present invention, or an AAV vector according to the present invention, or a pharmaceutical composition according to the present invention for the use as disclosed herein, wherein the nucleic acid, expression cassette, AAV vector or pharmaceutical composition is preferably administered to the central nervous system by intracerebral injection, intraparenchymal injection, intrathecal injection, intracisternal injection, intraventricular injection or a combination thereof, more preferably by convection enhanced delivery.

[0131] use

[0132] Another aspect of the present invention relates to the use of an AAV vector according to the present invention or a composition comprising an AAV vector. In one embodiment, an expression cassette according to the present invention, an AAV vector according to the present invention, or a pharmaceutical composition according to the present invention is provided for use as a medicament. In a further embodiment, a nucleic acid according to the present invention, an expression cassette according to the present invention, an AAV vector according to the present invention, or a pharmaceutical composition according to the present invention is provided for use in the treatment and / or prevention of tauopathy in a subject. In a further embodiment, a nucleic acid according to the present invention, an expression cassette according to the present invention, an AAV vector according to the present invention, or a pharmaceutical composition according to the present invention is provided for use in the treatment and / or prevention of Alzheimer's disease in a subject. In a further embodiment, a nucleic acid according to the present invention, an expression cassette according to the present invention, an AAV vector according to the present invention, or a pharmaceutical composition according to the present invention is provided for use in treatment as a medicament, wherein the subject is a carrier of an APOE4 allele, wherein preferably the subject is homozygous for the APOE4 allele.

[0133] Host cells and methods and kits for producing AAV vectors

[0134] In a further aspect, the invention relates to a method for producing a nucleic acid according to the invention, an expression cassette according to the invention, an AAV vector according to the invention or a pharmaceutical composition according to the invention.

[0135] Methods for producing nucleic acids of the invention include any method for producing nucleic acids, including but not limited to de novo synthesis, all of which will be clear to the skilled artisan.

[0136] The method for producing an AAV vector preferably comprises the steps of: a) culturing a host cell as defined above under conditions such that the AAV vector is produced; and b) optionally, one or more of recovering, purifying and formulating the AAV vector.

[0137] The host cell is preferably a host cell suitable for producing an AAV vector. Therefore, the host cell is a host cell suitable for in vitro culture, preferably large-scale culture. Host cells suitable for producing AAV vectors are well known in the art and will typically be mammalian or insect cell lines. The mammalian cell line used to produce an AAV vector is selected from any mammalian species, including but not limited to cells such as: A549, WEHI, 3T3, 10T1 / 2, BHK, MDCK, COS1, COS 7, BSC1, BSC 40, BMT 10, VERO, WI38, HeLa, HEK 293 cells (which express functional adenovirus E1), Saos, C2C12, L cells, HT1080, HepG2, and primary fibroblasts, hepatocytes and myoblasts, which are derived from mammals, including humans, monkeys, mice, rats, rabbits and hamsters. The selection of mammalian species providing cells is not a limitation of the present invention; the type of mammalian cells (i.e., fibroblasts, hepatocytes, tumor cells) is not a limitation of the present invention. Mammalian cell lines useful for producing AAV vectors include in particular the broad range of HEK293 cell lines, of which the HEK293T cell line is preferred.

[0138] The insect cell line used to produce the AAV vector can be any cell line suitable for producing heterologous proteins. Preferably, the insect cell allows the replication of the baculovirus vector and can be maintained in culture, more preferably in suspension culture. In a preferred embodiment, the insect cell allows the replication of recombinant parvovirus vectors (including rAAV vectors). For example, the cell line used can be derived from fall armyworm, fruit fly or mosquito, such as a cell line derived from Aedes albopictus. Preferred insect cells or cell lines are cells from insect species susceptible to baculovirus infection, including, for example, S2 (CRL-1963, ATCC), Se301, SeIZD2109, SeUCR1, Sf9, Sf900+, Sf21, BTI-TN-5B1-4, MG-1, Tn368, HzAm1, Ha2302, Hz2E5, High Five (Invitrogen, California, USA) and (US 6,103,526; Protein Sciences Corp., Connecticut, USA).

[0139] Therefore, in one embodiment, the expression cassette or construct is an insect cell compatible vector or a mammalian cell compatible vector."Mammalian cell compatible vector" should be understood as a nucleic acid molecule capable of productive transformation or transfection of mammalian cells or cell lines.Mammalian cell compatible vectors are well known in the art. "Insect cell compatible vector" should be understood as a nucleic acid molecule capable of productive transformation or transfection of insects or insect cells. Exemplary insect cell compatible vectors include plasmids, linear nucleic acid molecules, and recombinant viruses (such as baculoviruses). Any vector can be used as long as it is insect cell compatible. Mammalian or insect cell compatible vectors can be integrated into the genome of the cell, but the presence of the vector in the cell does not need to be permanent, and also includes transient episomal vectors. The vector can be introduced by any known means, such as by chemical treatment of the cell, electroporation, or infection.

[0140] AAV in the supernatant can be recovered and / or purified using suitable techniques known to those skilled in the art. For example, monolithic columns (e.g., in ion exchange, affinity or IMAC mode), chromatography (e.g., capture chromatography, fixed method chromatography and expanded bed chromatography), centrifugation, filtration and precipitation can be used for purification and concentration. These methods can be used alone or in combination. In one embodiment, capture chromatography methods (including column-based or membrane-based systems) are used in combination with filtration and precipitation. A suitable precipitation method can be easily selected by those skilled in the art, such as using polyethylene glycol (PEG) 8000 and NH 3 SO 4 . Thereafter, the precipitate may be treated with benzonase and purified using a suitable technique. Furthermore, the recovery may preferably include a step of affinity purification of the recombinant parvovirus (rAAV) vector (including its virions) using an anti-AAV antibody (preferably an immobilized antibody). The anti-AAV antibody is preferably a monoclonal antibody. Particularly suitable antibodies are single-chain camelid antibodies or fragments thereof, such as can be obtained, for example, from camels or llamas (see, for example, Muyldermans, 2001, Biotechnol. [Biotechnology]). 74 :277-302). Antibodies used for affinity purification of rAAV are preferably antibodies that specifically bind to an epitope on an AAV capsid protein, whereby preferably the epitope is an epitope present on the capsid protein of more than one AAV serotype. For example, an antibody can be generated or selected based on specific binding to AAV2 capsid, but at the same time it can also specifically bind to AAV1, AAV3 and AAV5 capsids.

[0141] In general, suitable methods for producing AAV vectors according to the invention in mammalian or insect host cells and therefore means such as expression constructs for expressing AAV rep proteins are described in the following literature, for mammalian cells: Clark et al. (1995, Hum. Gene Ther. [Human Gene Ther.] 6, 1329-134), Gao et al. (1998, Hum. Gene Ther. [Human Gene Ther.] 9, 2353-2362), Inoue and Russell (1998, J. Virol. [Journal of Virology] 72, 7024-7031), Grimm et al. (1998, Hum. Gene Ther. [Human Gene Ther.] 9, 2745-2760), Xiao et al. (1998, J. Virol. [Journal of Virology] 72, 2224-2232) and Judd et al. (Mol Ther. Nucleic Acids. [Molecular Therapy - Nucleic Acids] 2012; 1: e54), and for insect cells: Urabe et al. (2002, Hum. Gene Ther. [Human Gene Ther.] 13: 1935-1943), WO 2007 / 046703, WO 2007 / 148971, WO 2009 / 014445, WO 2009 / 104964, WO 2011 / 122950, ​​WO 2013 / 036118, WO 2015 / 137802, WO 2019 / 016349 and co-pending applications EP 21177449.2, PCT / EP2021 / 058794 and PCT / EP2021 / 058798, all of which are incorporated herein in their entirety.

[0142] In a further aspect, a kit is provided, comprising a nucleic acid according to the invention, an expression cassette according to the invention, an AAV vector according to the invention or a pharmaceutical composition according to the invention, wherein the kit further comprises an immunosuppressant.

[0143] In certain embodiments of the invention, immunosuppressive compounds can reduce and / or prevent the immune response induced by administration of the nucleic acids, AAV vectors, or pharmaceutical compositions of the invention.

[0144] In another aspect, the invention relates to a cell comprising a nucleic acid of the invention or an AAV of the invention, or a host cell.

[0145] In some embodiments, the cells of the present invention are prokaryotic cells. In some specific embodiments, the cells of the present invention are bacterial cells. In some embodiments, the cells of the present invention are eukaryotic cells. In some embodiments, the cells of the present invention are mammalian cells. In some embodiments, the cells of the present invention are insect cells.

[0146] The nucleic acid of the invention or the AAV vector of the invention can be delivered to the cell of the invention by any suitable method, including but not limited to transfection, transformation, transduction, nucleofection, electroporation, microinjection. For example, the expression cassette or nucleic acid of the invention can be contained in a plasmid contained in bacteria. The expression cassette or nucleic acid of the invention can also be contained in a production cell that produces, for example, a viral vector. The expression cassette can also be provided in a baculovirus vector.

[0147] Further details about host cells containing AAV vectors according to the invention have been provided elsewhere in this application. Any mammalian cell can be infected by the AAV vectors of the invention, including but not limited to muscle cells, hepatocytes, neural cells, glial cells or epithelial cells. In some preferred embodiments of the invention, the cells to be infected are human cells.

[0148] In another aspect, the invention relates to a method of treating or preventing a disorder, wherein the method comprises administering a nucleic acid of the invention or an AAV of the invention to a subject, thereby treating or preventing the disorder.

[0149] In another aspect, the invention relates to a nucleic acid of the invention or an AAV of the invention for use in the manufacture of a medicament for treating a disorder as detailed herein.

[0150] The invention has been described above with reference to a number of exemplary embodiments as shown in the accompanying drawings. Modifications and alternative embodiments of some parts or elements are possible and are included within the scope of protection as defined in the appended claims.

[0151] Examples

[0152] Materials and methods

[0153] Design of miRNA guide strands targeting APOE

[0154] The miAPOE miRNA guide strands were designed to target either a coding or noncoding RNA sequence of one of the human APOE transcripts ( FIG. 1 , SEQ ID NO. 1). Regions conserved between humans and non-human primates were identified, and 22 nt of target sequences were selected (SEQ ID NO. 2-93, Table 1) to generate different miRNA guide strands (SEQ ID NO. 94-185, Table 2). Scrambled miRNA guide strands were designed to generate negative controls (SEQ ID NO. 186-189). In addition, a scrambled miRNA guide (SEQ ID NO. 294) previously designed for a different research program was used for in vivo testing.

[0155] DNA constructs

[0156] The miAPOE and scrambled control guide sequences were embedded into the human pre-miR-451 scaffold ( Figure 2 a, SEQ ID NO. 190), flanked by 178 or 206 nt of 5' flanking sequence and 139 or 205 nt of 3' flanking sequence. The pre-miAPOE cassette is expressed from the CMV immediate early enhancer fused to the chicken β-actin promoter (CAG promoter, SEQ ID NO. 191) or adapted / synthetic promoters (P1, SEQ ID NO. 192 and P2, SEQ ID NO. 193), and terminated with the simian virus 40 polyadenylation signal (SV40 poly A, SEQ ID NO. 194).

[0157] The APOE transgene was expressed from a CAG promoter (SEQ ID NO. 191) or an adapted / synthetic promoter (P1, SEQ ID NO. 192 and P2, SEQ ID NO. 193) and terminated with SV40 poly A (SEQ ID NO. 194). The APOE sequence was codon optimized for Homo sapiens using an online codon optimization tool from ThermoFisher, and the NheI, NotI, and SpeI sites were kept intact during codon optimization. miAPOE (SEQ ID NO. 108, 116, 146) or scrambled negative control (SEQ ID NO. 186) and APOE transgene (SEQ ID NO. 195, 197, 200, 196, 198, 201, 206, 208, 210, 207, 209, 211, 214, 216, 216) were combined to promote simultaneous knockdown of APOE4 and overexpression of protective APOE variants (combination approach). Plasmid DNA constructs carrying the pre-miAPOE cassette and the APOE transgene cassette containing intronic elements of the P2 promoter were synthesized with added 5' (BlpI) and 3' (EcoRV) sequences and subcloned by Genewiz (Azenta Life Sciences). Combination Methods Expression of constructs was driven by the P4 promoter (P3, SEQ ID NO. 232 plus intronic elements, SEQ ID NO. 231) and terminated with the SV40 poly A signal (SEQ ID NO. 194). The identity of each construct was confirmed by sequencing.

[0158] Generate an APOE4 luciferase reporter containing a complementary APOE target region (1166 bp, SEQ ID NO. 218) fused to the Renilla luciferase (RL) gene ( Figure 3The target sequence was synthesized with added 5' (XhoI) and 3' (PmeI) sequences and cloned by GeneWeiZ (Ascenda Life Sciences) into the 3'UTR of the Renilla luciferase (RL) gene in the psiCHECK-2 vector (Promega, Madison, WI).

[0159] AAV5 vector

[0160] Recombinant AAV5 particles were produced by infecting serum-free SF+ insect cells (Protein Sciences, Meriden, CT, USA) with two baculoviruses, one encoding the Rep / Cap combination and the second carrying the transgene construct. The titer of the purified AAV was determined using QPCR after a standard protein purification procedure using AVB agarose (GE Healthcare) on a fast protein liquid chromatography system (AKTA Avant 150, GE Healthcare).

[0161] Recombinant AAV5 and AAV9 were also produced by PEI transfection of HEK293T cells with two plasmids encoding Rep-Cap and the transgene (Sirion Biotech). TM CaptureSelect TM After primary capture with AAV-X resin (Thermo Fisher Scientific) and two-step purification with an iodixanol gradient, the titer of purified AAV was determined using QPCR.

[0162] Transfection experiments

[0163] Human hepatocellular carcinoma (Huh7), human embryonic kidney 293T (HEK293T) or U118 astrocytoma cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum without antibiotics. The day before the transfection or transduction experiment, cells were seeded in 24-well plates at a density of 1E+05 cells / well.

[0164] According to the manufacturer's protocol, use 2000 or 3000 for transfection.

[0165] Luciferase assay

[0166] HEK293T cells were co-transfected with miAPOE or combined constructs together with luciferase reporters containing both RL genes and firefly luciferase (FL) genes fused to the APOE target sequence. pBluescript was added to transfer equal amounts of DNA. Transfected cells were harvested in 100 μl 1x passive lysis buffer (Promega, Thermo Fisher Scientific) for 15 minutes at room temperature 48 hours after transfection. Cell lysates were centrifuged at 4,000 rpm for 5 minutes, and 10 μl supernatants were used to measure FL and RL activities with a dual luciferase reporter assay system (Promega, Thermo Fisher Scientific). Relative luciferase activity was calculated as the ratio between RL and FL activity.

[0167] Transduction experiments

[0168] For transduction, HEK293T cells were seeded in 24-well plates at a density of 1E+05 cells / well 1 day before transduction. The next day, cells were incubated with AAV vectors at a multiplicity of infection (MOI) of 1E+04, 1E+05E, and 1E+06 gc / cell. Cells and culture supernatants were harvested 2 days after transduction.

[0169] To transduce U-118 MG cells ( HTB-15 TM ), 1 day before transduction, cells were plated at 2.63E+4 cells / cm 2 The cells were inoculated at a density of 1.55E+06 gc / cell in 12-well or 24-well plates. The next day, the cells were incubated with AAV vectors at a multiplicity of infection (MOI) of 1.55E+06 gc / cell. The cell culture medium was replaced 2 days after transduction, and the cells were harvested 3 days after transduction for isolation of DNA and RNA.

[0170] Cryogenic pulverization of mouse tissue

[0171] Use automated low temperature sample crushing system to crush frozen tissue samples. Use CryoPREP system model CP02 (Covaris) to crush the quick-frozen tissue by applying one or more punches of different impact forces. Before and after each impact, the tissueTUBE (Covaris) with tissue is immersed in liquid nitrogen, and the procedure is repeated until the sample is crushed. The powder is stored in a cryovial (Covaris or Corning) at -80 ° C until further use (e.g., DNA and RNA extraction, lysate production for APOE protein measurement).

[0172] Vector DNA and mRNA isolation and quantification

[0173] The DNA was isolated using the All Prep 96 DNA / RNA Isolation Kit (Qiagen, 80311), All Prep DNA / RNA Mini Kit (Qiagen, 80204), or MagMAX TM mirVana TM DNA and RNA extraction for in vitro experiments was performed using the Total RNA Isolation Kit (Thermo Fisher Scientific). Cells were harvested in lysis buffer according to the manufacturer's protocol.

[0174] DNA and RNA extraction for in vivo experiments were performed using All Prep 96 DNA / RNA Isolation Kit (Qiagen, 80311) or All Prep DNA / RNA Mini Kit (Qiagen, 80204). Tissue lysates were produced by homogenizing in a TissueLyser II (Qiagen) at a frequency of 30 Hz for 60 seconds by adding the crushed tissue to a Lysing Matrix D tube (MP Biomedicals) with RLT lysis buffer and beta mercaptoethanol (Sigma) provided.

[0175] Using a spectrophotometer ( DNA and RNA concentrations and purity ratios were quantified in duplicate using Synergy HT (BioTek) or NanoDrop One or 2000 (ThermoScientific) in N120 (IMPLEN) or Take3 microvolume plates. Samples were stored at -80°C until further use.

[0176] After extraction, DNA concentrations were normalized to ensure equal input for quantitative polymerase chain reaction (qPCR). Vector genome copies were quantified by using a TaqMan qPCR assay (SEQ ID NO. 219-222 and SEQ ID NO. 277; Table 4) using a linearized plasmid standard (5E+0 to 5E+7) and ACTB TaqMan [human ACTB primer / probe mixture Hs01060665_g1 (Thermo Fisher Scientific)] and (SEQ ID NO. 225-227; Table 4) or SybrGreen qPCR (SEQ ID NO. 223-224; Table 4) assay as a loading control.

[0177] After extraction, RNA concentration was normalized before DNase treatment to ensure equal input for cDNA synthesis and subsequent qPCR. RNA was isolated using the TURBO DNAse TM DNase treatment of isolated RNA was performed with the DNase provided with the Maxima First Strand cDNA Synthesis Kit (K1672), and for cDNA synthesis, the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) was used according to the manufacturer's instructions. WT and codon-optimized variants V2 and V3 APOE mRNA expression was quantified using single or dual qPCR using TaqMan qPCR assays (SEQ ID NOs. 228-230 for WT APOE and SEQ ID NOs. 287-291 for codon-optimized variants; Table 4) and β-actin ACTB TaqMan [human ACTB primer / probe mixture Hs01060665_g1 (Thermo Fisher Scientific), mouse ACTB primer / probe mixture mm01205647_g1 (Thermo Fisher Scientific)] or SybrGreen qPCR assays (SEQ ID NOs. 223-224; Table 4) as reference genes for normalization. Absolute or relative gene expression levels were calculated using ddCT (Livak's Method) or using linearized plasmid standards (1E+8 to 1E+3 or 1E+2).

[0178] qPCR was performed using the QuantStudio 5 Real-Time PCR System or the 7500 Fast Real-Time PCR System (Thermo Fisher Scientific). The lower limit of quantification (LLOQ) was determined by calculating the copy number at the mean Ct value of the lowest point of the standard system and corrected for the input (ng) of (c)DNA used.

[0179] Table 4. Primers and probes.

[0180]

[0181] miRNA RT-qPCR and quantification

[0182] DNase treatment and cDNA synthesis of isolated RNA from in vivo experiments were performed using the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) and the E. coli poly (A) polymerase kit (New England Biolabs) according to the manufacturer's instructions. For reverse transcription, the RT primers indicated in Table 5 were used.

[0183] The miRNA expression was quantified using SybrGreen qPCR assays specific for each miRNA (SEQ ID NOs. 278-286 and SEQ ID NOs. 292-293 in Table 5). For the in vivo hAPOE4-Tr mouse study, relative miRNA expression was calculated using standard lines obtained from each RNA oligonucleotide, respectively (22 NT for miAPOE-016, miAPOE-037, and miAPOE-145, and 23 NT for miSCR1-C9O). Based on the in vitro small RNA sequencing data, the assay was optimized for the in vivo WT mouse study, and standard lines were generated from RNA oligonucleotides with the most abundant isoform size (24 NT for miAPOE-016, 25 NT for miAPOE-037, 24 NT for miAPOE-145, and 23 NT for miAPOE_SCR).

[0184] The lower limit of quantification (LLOQ) is the lowest amount of analyte in a sample that can be reliably quantified with an acceptable level of precision. This is calculated using the lower point of the standard set (reliably quantifiable) and obtaining the corresponding copies per ng RNA.

[0185] The lower limit of detection (LLOD) is the lowest amount of analyte in a sample that can be reliably detected but not necessarily quantified. This is calculated using the lowest Ct value detectable by the machine and obtaining the corresponding copies per ng of RNA.

[0186] Table 5. List of primers used for miRNA RT-qPCR and quantification.

[0187] SEQ ID NO. ID Sequence (5'->3') 278 RT Primer CAGGTCCAGTTTTTTTTTTTTTTTVN 279 prmiAPOE16FW22 AGCACAGAACCTTCATCTTC 280 prmiAPOE16RV22 GTCCAGTTTTTTTTTTTTTTTGCAG 281 prmiAPOE37FW222324 GTGACCAGCAACGCA 282 prmiAPOE37RV23 AGGTCCAGTTTTTTTTTTTTTTTAGG 283 prmiAPOE145FW222324 CAGTCCAGTTCCGATTTGTAG 284 prmiAPOE145RV23 GGTCCAGTTTTTTTTTTTTTTTGAG 285 miSCR1-C9O_23nt-FW AGGCGACTTGTAACGTCA 286 miSCR1-C9O_23nt-RV CAGTTTTTTTTTTTTTACGCCTCT 292 prmiAPOESCRFW222324 CGCGTTCTCGCTGTTC 293 prmiAPOESCRRV22 GGTCCAGTTTTTTTTTTTTTTTAGTC

[0188] RNA Isolation for Small RNA Sequencing and Poly A-Enriched mRNA Sequencing

[0189] For in vivo, pulverized tissue was lysed at 30 Hz for 60 seconds in Lysing Matrix D tubes (MP Biomedical) with RLT lysis buffer and β-mercaptoethanol (Sigma) using TissueLyser II (Qiagen). RNA was extracted using miRNeasy Tissue / Cell Advanced Mini Kit (Qiagen) according to the manufacturer's protocol. For in vitro, transduced cells were harvested and lysed in TRIzol TM Reagent (Invitrogen). Direct-zol TM RNA was extracted using the RNA MiniPrep Kit (Zymo Research R2052). Nucleic acid concentration and purity were measured in duplicate using the NanoDrop TMOne (Thermo Scientific) was used for RNA quantification. The quality of RNA samples was analyzed using Agilent high-sensitivity RNA screening bands (Agilent) before shipment. The samples were stored at -80°C and shipped on dry ice to GenomeScan for small RNA sequencing (Illumina NovaSeq6000 sequencing, paired ends, 150bp. About 3Gb per sample, 10 million paired-end reads) and poly A-enriched mRNA sequencing (Illumina NovaSeq6000 sequencing, paired ends, 150bp. About 9Gb per sample, 30 million paired-end reads).

[0190] RNAseq data analysis

[0191] The original RNASeq data was provided by GenomeScan. For data analysis, CLC GenomicsWorkbench version 21.0.5 was used. For small RNA sequencing analysis of both in vivo and in vitro derived samples (hAPOE4-Tr mouse tail cortex or transduced U-118MG cells were administered respectively), the obtained data were aligned and annotated with respect to the miAPOE or miSCR reference sequence (SEQ ID no.295-297; Table 7). The length and match of mature miRNA subtypes were identified, and their abundance was calculated as the percentage of total reads mapped to the reference miAPOE or miSCR sequence. During the analysis, for convenience, 2% of the mature form was taken as the threshold. Small RNA sequencing analysis was performed using CLC Genomics Workbench Toolbox, and the endogenously expressed miRNA levels were sorted together with the miAPOE or miSCR transcript levels by correcting the reads (in counts per million (CPM)). miR-29a-3p and miR-16-5p, which are miRNAs expressed in the brain, were used as internal controls.

[0192] For mRNA sequencing analysis of in vitro derived samples (transduced U-118MG cells), the data obtained were aligned and annotated with respect to the host species (Homo sapiens for transduced U-118MG experiments). Differential expression for RNA-Seq was obtained using CLC Genomics Workbench Toolbox, where the datasets obtained from samples transduced with the AAV5 combinatorial approach or single constructs were compared to the datasets obtained from samples transduced with AAV5-miSCR (control).

[0193] Table 7. miAPOE and miSCR reference sequences

[0194]

[0195] APOE protein measurement

[0196] APOE concentration in cell culture supernatant was quantified using human apolipoprotein E (APOE) ELISA kit (ab108813, Abcam). This kit identifies all three human APOE subtypes (APOE2, APOE3 and APOE4). Several dilutions of the test cell culture supernatant samples were accurately measured within the standard range provided. For HEK293T cells transfected with an APOE expression construct, the cell culture supernatant was diluted 100 times in the ELISA assay buffer provided. After sample preparation, APOE was measured using the provided protocol of the kit and the concentration was quantified using a four-parameter logistic curve fit in PRISM.

[0197] APOE concentration in tissue lysates was quantified using the human apolipoprotein E (APOE) MSD R-PLEX assay (K1512IR-2, MesoScale Discovery). Tissues were lysed in MSD Tris lysis buffer (R60TX-2, MesoScale Discovery) and quantified using Pierce TM The total protein concentration was corrected with 660nm protein assay reagent (22660, Thermo Fisher Scientific). The lysate of 2mg / ml total protein was diluted 50 times in MSD diluent 100 (R50AA-2, mesoscale discovery). After sample preparation, APOE was measured using the protocol provided by the kit and the concentration was quantified using MSD Discovery Workbench (software version 4.0).

[0198] Phosphorylated tau (pTau181) and total tau measurements

[0199] pTau181 protein concentration was quantified using the human pTau181 MSD S-PLEX assay (K151AGMS, Mesoscale Discovery) and total tau protein was measured in mouse hippocampal tissue lysates using a multi-point phosphorylation (Thr231) / total tau protein assay (K15121D, Mesoscale Discovery). Tissues were lysed in MSD Tris lysis buffer (R60TX-2, Mesoscale Discovery) and quantified using Pierce TM660nm protein assay reagent (22660, Thermo Fisher Scientific) is normalized to total protein concentration. Hippocampal lysates were diluted 10000 times in dPBS for pTau181 determination, or 200 times in dPBS for total tau protein determination. The samples were then further diluted 2 times in the blocking buffer provided with the respective kits. After sample preparation, pTau181 and total tau protein concentrations were measured using MSD Methodological Minds software using the protocols provided by the two kits, and further processed using MSD Discovery Workbench (software version 4.0).

[0200] SDS-PAGE and western blotting

[0201] Samples were prepared in 1x Laemmli sample buffer (1610747; Bio-Rad) and heated to 95°C for 5 min. Proteins were separated on Mini-PROTEAN TGX stain-free protein gels 4%-20% (4568093; Bio-Rad) and stained using Trans-blot Turbo Mini PVDF transfer kit (1704156; Bio-Rad) and Trans-Blot Turbo TM The samples were transferred to PVDF membrane using a transfer system (1704150; Bio-Rad).

[0202] The PVDF membrane was blocked with SuperBlock T20 (PBS) blocking buffer (37516; Bio-Rad) and stained with primary antibodies in blocking buffer. After washing with 0.5% Tween-20 in phosphate buffered saline (PBS), the membrane was incubated with secondary antibodies in blocking buffer. After extensive washing with PBS-0.5% Tween20, proteins were visualized using SuperSignalTM WestPico PLUS chemiluminescent substrate (34580; Thermo Scientific) and ChemiDoc Touch gel imaging system (1708370; Bio-Rad).

[0203] The following primary and secondary antibodies against the respective proteins were used: APOE (Sigma Aldrich; HPA065539 and HPA068768), polyclonal goat anti-rabbit IgG-HRP (DAKO, P0448) (DAKO), polyclonal rabbit anti-mouse IgG-HRP (DAKO, P0260)

[0204] Recombinant human APOE protein (Sigma-Aldrich; SRP4760, SRP4696, A3234) or apolipoprotein E from human plasma (Sigma-Aldrich; SRP6303) of known concentration were used as references.

[0205] Animal studies

[0206] To investigate the efficacy of miAPOE, the transgenic model B6.129P2-APOE carrying the human APOE4 gene was used. tm3 (APOE*4)Mae At eight weeks of age, male B6.129P2-Apoe were treated with a single bilateral intrastriatal (IS) administration of empty AAV5, AAV5-miSCR (SEQ ID NO. 186), or AAV5-miAPOE_016 (SEQ ID NO. 108) (medium and high doses), or AAV5-miQURE-miAPOE_037 (SEQ ID NO. 116) (medium and high doses), or AAV5-miAPOE_145 (medium and high doses), or AAV9-miAPOE_145 (medium and high doses) (SEQ ID NO. 146). tm3 (APOE*4)Mae N8 mice were treated. Each group contained 8 animals. Body weight (individual) was determined before treatment and then determined once a week. Before treatment, 3, 6 and 8 (sacrificed) weeks after treatment, blood samples were collected from mice to prepare plasma. Plasma total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL) (all for each individual mouse) at all time points were determined in the collected plasma samples. Mice were sacrificed 8 weeks after treatment. Multiple organs and CSF were collected for analysis of AAV transduction, APOE mRNA expression, hAPOE4 expression levels and miAPOE transgenic expression by qPCR.

[0207] In order to study the expression of APOE3ch in C57B16 mice, 8 mice per group were injected with a single bilateral intrastriatal dose of vehicle, AAV5 or AAV9 vector, or a single bilateral dose of AAV5 or AAV9 vector was injected intraventricularly. All AAV vectors carry an APOE3ch expression cassette with a double HA tag. Blood samples were taken before administration, 2 weeks after administration, and 4 weeks (sacrifice). In the 4th week after treatment, animals were sacrificed. After perfusion, peripheral blood and CSF samples were taken for each animal. Several brain regions, spinal cords, and livers of 5 animals per group were collected and quickly frozen. For 3 animals per group, the brain was fixed for immunohistochemistry and FISH purposes.

[0208] The efficacy of AAV5 vectors encoding different APOE variants in changing the phenotype of the tauopathy model P301S mice (PS19, JAX strain: 008169) was evaluated by a single bilateral intrastriatal injection of AAV vectors. Twelve male mice in each group will be treated at 8 weeks of age. Body weight will be measured before treatment and once a week thereafter. Blood samples will be taken before treatment and at weeks 2, 4, 12 and 20 after treatment. A set of markers will be analyzed from plasma for the following parameters: LDL, HDL, cholesterol and triglycerides on peripheral plasma samples. Behavioral tests will be performed on mice to assess motor and cognitive function. At 28 weeks after treatment, peripheral blood and CSF samples will be collected. Several different brain regions, different spinal cord segments and livers of animals of 8 mice per group will be collected and quickly frozen. The brains of the remaining 4 animals will be perfused and fixed for IHC and FISH purposes.

[0209] The in vivo expression level of the transgene achieved by the combination approach constructs compared to the single constructs was evaluated by a single bilateral intrastriatal administration of AAV vectors in WT mice. Six mice per group were treated at eight weeks of age. Animals were sacrificed one month after treatment. Multiple brain regions and livers of 5-6 animals per group were collected and snap frozen.

[0210] In patients also carrying hAPOE4(B6.129P2- APOEtm3(APOE*4)Mae N8 A single bilateral intrastriatal administration of an AAV vector was used in a tauopathy model P301S mouse (PS19, JAX strain: 008169) to evaluate the in vivo expression level and the effect on tauopathy of an AAV encoding a transgenic AAV derived from a combinatorial method construct compared to a single construct. Six mice per group were treated at eight weeks of age. Animals were killed several months after treatment. Multiple brain regions, livers, and biofluids from all animals in each group were collected and quickly frozen.

[0211] In silico evaluation of potential off-target transcripts of the miAPOE guide

[0212] BLASTN against the human reference transcriptome was used (via ENSEMBL, https: / / www.ensembl.org / Homo_sapiens / Tools / Blast , see Table 8 for description, Bedell et al., 2003) performed in silico off-target prediction of miAPOE miRNA guide sequences to identify transcripts that are partially complementary to the 22-nucleotide miAPOE guide sequences (SEQ ID NOs. 108, 116, and 146).

[0213] Table 8: Description of BLASTN for in silico off-target prediction

[0214] Search sensitivity: short sequence Search Type BLASTN Maximum number of hits reported 100 Report the maximum E value of the alignment 1000 Word length used to seed the comparison 7 Match / Mismatch Score 1,-3 Filtering low complexity areas no Use Repeat masker to filter query sequences yes

[0215] The “siRNA Seed Potential of Off-Target Reduction” tool (siSPOTR, Boudreau et al., 2013) was used to predict the binding of the miAPOE miRNA guide seed sequence (nucleotides 2-8) to off-target transcripts.

[0216] result

[0217] Example 1: In vitro testing of miAPOE constructs on the APOE4 Luc reporter system

[0218] To test the knockdown efficiency of the designed miAPOE constructs, HEK293T cells were co-transfected with miAPOE (SEQ ID NOs. 94-185) expression constructs and an APOE4 luciferase reporter carrying complementary APOE target regions (SEQ ID NOs. 2-93).

[0219] First, since exogenous expression of miR-144 (SEQ ID NO. 235) will lead to side effects (e.g., miR-144 target engagement) (Huang et al. 2021; H. Li et al. 2016; Lin et al. 2020), a novel strategy was designed to introduce modifications within the scaffold to eliminate miR-144 expression. A mutant form of the engineered miR-144 (SEQ ID NO. 236) hairpin, in which adenosine at position 5 from the Drosha cleavage site was replaced by thymidine (T), produced a bulge near the cleavage site, which disrupted the expression of miR-144 (S. Li et al. 2020, 2021).

[0220] Any mismatch, bulge or GU wobble introduced at position 4-8 from the Drosha cleavage site impairs the enzymatic activity of Drosha. Double and triple mismatches, bulges or wobble within the 4-8 segment further reduce the activity of Drosha. Therefore, any of the following SNPs and combinations thereof within the 4-8 nucleotide segment of miR-144 can alter (precursor) miR-144 expression. These mutations include U>G at position 4, and / or A>U or G at position 5, and / or U>A at position 6, and / or C>G or U at position 7, and / or A>U or G at position 8.

[0221] Next, a set of scaffolds expressing synthetic miRNA6 (=miHTT) from miR-451 was generated, either as a single hairpin (SEQ ID NO. 238) or mixed with miR-144 wild type (miR-144WT auxiliary) (SEQ ID NO. 239) or miR-144 mutant (miR-144A>T auxiliary) (SEQ ID NO. 240). miRNA6 expression was evaluated in different scaffolds by small RNA sequencing ( Figure 3 A). The introduced bulge abolished miR-144 5p and 3p expression without affecting its auxiliary function to miR-451, as shown by the expression values ​​of miRNA6 remaining unaffected when mixed with miR-144WT auxiliary or miR-144A>T ( Figure 3 A).

[0222] Thereafter, the expression values ​​of a batch of different synthetic miRNA sequences (SEQ ID NO. 241-248) expressed from the miR-451 scaffold (without and with the miR-144A>T helper) (SEQ ID NO. 190) were also analyzed, confirming the unexpected and dramatic improvement of the synthetic miRNAs expressed by miR-451 in the presence of miR-144A>T (SEQ ID NO. 236) ( Figure 3 B). Thus, the use of mutant auxiliary miR-144 enables the use of miR-144-miR-451 activity without the expression of unwanted microRNAs and allows for higher synthetic miRNA expression levels. Therefore, the miR-144A>T mutant-miR-451 cluster was selected for use.

[0223] Primary screening was performed on HEK293T cells co-transfected with 250 ng miAPOE (SEQ ID NO. 94-185) or miSCR constructs (SEQ ID NO. 186-189) and 50 ng reporter constructs. Two days after transfection, cells were harvested to measure luciferase expression. Luciferase expression in the presence of miSCR was set to 100%.

[0224] Compared to the miSCR construct (SEQ ID NO. 186), most transfected miAPOE constructs showed a decrease in relative luciferase activity. miAPOE with SEQ ID NO. 96, 105, 106, 108, 113, 115, 116, 131, 132, 133, 134, 135, 136, 137, 139, 146, 149 resulted in a knockdown of reporter activity of ≥ 70% ( Figure 4 ).

[0225] To further accurately determine the efficacy of miAPOE constructs, effective miAPOE constructs with more than ≥ 60% knockdown efficiency were tested in titration experiments using 2, 10 or 50 ng miAPOE (SEQ ID NO. 96, 99, 100, 105, 106, 108, 109, 113, 114, 115, 116, 117, 131, 132, 133, 134, 135, 136, 137, 139, 143, 146, 149, 151, 185) or miSCR construct (SEQ ID NO. 186) and 10 ng reporter construct (n = 2). Luciferase expression in the presence of miSCR was set to 100%. All constructs showed dose-dependent reporter knockdown ( Figure 5 ).

[0226] Example 2: In vitro testing of miAPOE - knockdown of endogenous APOE (mRNA and protein)

[0227] The ability of miAPOE candidates to silence endogenously expressed APOE mRNA and reduce APOE protein levels was tested in Huh7 cells.

[0228] Huh7 cells were co-transfected with 250ng of miAPOE (SEQ ID NO.94-185) or miSCR constructs (SEQ ID NO.186-189). APOE mRNA expression was determined using RT-QPCR and calculated using β-actin gene expression as a reference gene using the ddCT method. Compared to the average of the four SCR constructs (pBluescript and untransfected were set as 100%), most of the transfected miAPOE constructs had reduced APOE mRNA. miAPOE SEQ ID NO.96, 98, 99, 108, 109, 113, 115, 116, 136, 138, 144, 146, 149, 151, 160, 163, 171 and 185 reduced endogenous APOE mRNA expression by >50% or more ( Figure 6 ).

[0229] Nine miAPOE constructs that showed ≥60% reduction in reporter activity in previous experiments were selected to test targeting at lower doses. Huh7 cells were co-transfected with 50ng or 250ng miAPOE (SEQ ID NO.96, 108, 116, 133, 136, 138, 146, 151, 185) or miSCR constructs (SEQ ID NO.186-187) and 10ng pFI reporter constructs as described above. APOE mRNA expression of the average miSCR sample was set to 100% expression. All constructs showed ≥60% reduction in APOE mRNA after transfection with 250ng plasmid and ≥50% reduction after transfection with 50ng plasmid ( Figure 7 In addition, APOE protein levels in culture supernatants were quantified using Western blot in 250 ng transfected samples. Quantification of APOE protein levels in transfected cell supernatants relative to untransfected cells showed a 70%-90% reduction in all tested miAPOE ( Figure 8 ).

[0230] Example 3: In vitro testing of endogenous APOE mRNA expression in Huh7 cells after transduction with AAV-miAPOE

[0231] Recombinant AAV (5 or 9) vectors carrying expression cassettes of miAPOE_016 (SEQ ID NO.108), miAPOE_037 (SEQ ID NO.116), miAPOE_145 (SEQ ID NO.146) and miSCR_144 (SEQ ID NO.186) were generated. The ability of the obtained AAV to transduce and deliver the packaged expression cassettes was tested by transducing Huh7 cells at a multiplicity of infection (MOI) of 5E+06, 3.6+06, 1E+06, 5E+05 or 5E+04 gc / cell. Vector DNA copies and residual APOE mRNA were evaluated by qPCR and RT-QPCR using TaqMan qPCR duplexes 48h after transduction. Vector DNA levels were quantified using a standard system ranging from 1E+07 to 5E+01 copies. A dose-dependent increase in detected vector genomic DNA copies was observed. The transduction efficiency of Huh7 cells was comparable for all AAV5 batches at the same MOI. AAV9 vectors showed lower vector genome copies in Huh7 cells after transduction. Similar to AAV5 vectors, there was a dose-dependent increase in vector copies detected after transduction ( Fig. 9 A).

[0232] Endogenous APOE mRNA expression was calculated using the ddCT method using β-actin as a reference gene. APOE mRNA expression in the presence of AAV5-miSCR was set to 100% expression. The results are depicted in Fig. 9 In B.

[0233] All AAV batches resulted in a dose-dependent reduction in APOE mRNA expression, confirming the functionality of the AAV-delivered expression cassette and the efficacy of miAPOE. AAV5-miAPOE_037 (AAV5) and AAV5-miAPOE_016 also showed a clear dose-dependent reduction: miAPOE_037 showed the greatest efficacy in reducing APOE mRNA expression at MOI 5E+06gc / cell (reduction of approximately 55%) and MOI 1E+06gc / cell (reduction of approximately 35%), with little reduction observed at MOI 5E+05gc / cell (reduction of approximately 10%), and no reduction at MOI 5E+04gc / cell. Similarly, miAPOE_016 showed the highest reduction at MOI 5E+06 (about 35% reduction), MOI 1E+06 (about 25% reduction), and 5E+05 for MOI 5E+05 (about 15% reduction).

[0234] For AAV5-miAPOE_145, a decrease of approximately 15% in APOE mRNA expression at MOI 5E+06 and approximately 25% at MOI 1E+06 was observed, and a similar range of decrease was observed in the case of AAV9-miAPOE_145.

[0235] Example 4: Testing of AAV-miAPOE Targeting APOE in hAPOE4TR Mice

[0236] To examine the ability of the selected miAPOE candidates to silence human APOE4 expression in vivo, the hAPOE4 targeted replacement (TR) mouse model was used. Male mice were treated with empty AAV5, AAV5-miSCR (SEQ ID NO.294, previously incorrectly labeled as SEQ ID NO.186), or AAV5-miAPOE_016 (SEQ ID NO.108) (medium dose and high dose), or AAV5-miQURE-miAPOE_037 (SEQ ID NO.116) (medium dose and high dose), or AAV5-miAPOE_145 (medium dose and high dose), or AAV9-miAPOE_145 (medium dose and high dose) (SEQ ID NO.146) by single bilateral intrastriatal (IS) administration. The medium dose was set to a total of 6E10 gc per mouse, and the high dose was set to a total of 3E11 gc per mouse. Each group contained 8 animals. At 8 weeks post-treatment, animals were sacrificed and levels of vector DNA, APOE mRNA, miAPOE or miSCR, and hAPOE4 protein in the brain were determined.

[0237] AAV transduction was analyzed by quantifying vector DNA levels by qPCR. All mice treated with AAV5-miSCR, AAV5-miAPOE_016, AAV5-miAPOE_037, AAV5-miAPOE_145, and AAV9-miAPOE_145 showed a significant increase in vector DNA levels in the striatum and cortex, reaching up to 2.05E+08 gc / μg DNA and 2.54E+07 gc / μg DNA, respectively ( Fig.16 A- Fig.16 B) The absence of a dose-dependent increase in vDNA indicates that both doses reached transduction saturation.

[0238] The silencing of human APOE mRNA by the selected miAPOE candidates (miAPOE_016, miAPOE_037 and miAPOE_145) was evaluated via RT-qPCR. In the striatum, AAV5-miSCR showed similar mRNA levels compared to the empty AAV5 group (3.82E+07 copies / μg RNA). Compared with AAV5-miSCR, a significant reduction of up to> 80%-90% of hAPOE4 mRNA levels was observed in mice injected with AAV-miAPOE candidates (Figure 17A-Figure 17B). In the frontal cortex, the variation between hAPOE4 mRNA levels was found in mice injected with empty AAV5 or AAV5-miSCR. Compared with AAV5-miSCR, a reduction of> 50%-60% of hAPOE4 mRNA was observed in mice injected with AAV-miAPOE candidates (Figure 17C-Figure 17D).

[0239] In addition, miRNA (miAPOE or miSCR) levels were quantified by SYBRgreen RT-qPCR assay using specific primers for mature miAPOE and miSCR of 22 or 23 nucleotides in length. The miRNA levels in the striatum of mice injected with AAV-miAPOE reached as high as 2.45E+11 copies / μg total RNA ( Fig.18 ). It was found that mice injected with AAV5-miSCR had 1.45E+08 miRNA copies / μg total RNA. Striatal tissue from mice injected with empty AAV5 was also taken in all RT-qPCR experiments using specific primers for miAPOE or miSCR. In all experiments, the amount of miRNA copies / μg total RNA in the striatum of mice injected with empty AAV5 was below the LLOQ (not shown).

[0240] To examine whether silencing of hAPOE4 mRNA was associated with reduced hAPOE4 protein levels, hAPOE-MSD was performed on frontal cortex tissue. The hAPOE4 protein levels of mice injected with AAV5-miSCR were equal to the control level (empty AAV5) of 41 ng / mg, again confirming that AAV5-miSCR did not affect hAPOE4 protein levels ( Fig.19 ). Significant protein reductions of up to >50%-60% were observed in mice injected with AAV-miAPOE candidates compared to AAV5-miSCR.

[0241] To examine the processing and abundance of expressed miAPOE compared to the expression levels of endogenous miRNAs, RNA was isolated from the tail cortex of two mice from the high-dose group (AAV5-miAPOE_016, AAV5-miAPOE_037, and AAV5-miAPOE_145) and analyzed by small RNA sequencing. Data analysis revealed that the expected read counts of miAPOE transcripts ranged from 4.57% to 0.32% when compared to total miRNA reads (Figure 20B). The most abundant isomirs produced by miAPOE_016, miAPOE_037, and miAPOE_145 were 23, 25, and 24 nucleotides long, respectively (Figure 20A). The total miSCR and miAPOE reads of all samples were compared to the expression levels of endogenous miRNAs (Figure 20C). Considering that miAPOE is not among the most abundant endogenously expressed miRNAs, the risk of miAPOE oversaturating the RNAi pathway is very low. Two internal controls, miR-29a-3p and miR-16-5p, showed consistent abundance in all samples, ranking 10.5±1 (SD) and 37.37±2.44 (SD), respectively (marked in Figure 20C). In summary, these results demonstrate high levels of vDNA and miRNA in vivo, as well as significant reductions in hAPOE4 mRNA and protein levels of AAV-miAPOE candidates. Therefore, these results demonstrate that high levels of miRNAs are being expressed following expression of miAPOE delivered via AAV, resulting in significant reductions in hAPOE4 mRNA and protein levels.

[0242] Example 5: In vitro testing of overexpression of APOE variants

[0243] APOE expression constructs were transfected into HEK293T cells, and APOE protein expression was measured in the supernatant two days after transfection. The following APOE constructs were tested: APOE2ch WT (R136S mutation, SEQ ID NO. 197), APOE2chv1 and APOE2ch v2 (variants codon-optimized for Homo sapiens using the online codon optimization tool from Thermo Fisher Scientific, SEQ ID NOs. 204, 208), APOE2 WT (SEQ ID NO. 195) and APOE2 v1 and v2 (2 codon-optimized variants, SEQ ID NOs. 202, 206), APOE3 WT (SEQ ID NO. 196) and APOE3 v1 and v2 (codon-optimized variants, SEQ ID NOs. 203, 207) and APOE3ch WT (R136S mutation, SEQ ID NO. 198), APOE3chv1 and APOE3ch v2 (codon-optimized variants, SEQ ID NOs. 205, 209).

[0244] APOE protein expression was detected in all cells transfected with the different APOE constructs ( Fig.10 A). Recombinant APOE3 protein served as a positive control. The WT forms of all constructs of APOE2ch, APOE3ch, APOE2, and APOE3 showed the highest protein expression among the different variants. In addition, the expression of APOE constructs in astrocytoma cells was confirmed ( Fig.10 B).

[0245] Example 6: In vitro testing - APOE variant expression in HEK293T cells after transduction with AAV5-APOE variants

[0246] To investigate the ability of AAV5-APOE variants to transduce and deliver packaged expression cassettes, HEK293T cells (n=1) were transduced at a multiplicity of infection (MOI) of 1E+04, 1E+05, 1E+06 gc / cell. Vector DNA levels in cells were quantified by qPCR. APOE variant protein expression in the culture supernatant of cells transduced with 1E+05, 1E+06 gc / cell was analyzed by Western blot as previously described. The results are depicted in Fig.11 A. All five AAV5-APOE batches tested resulted in dose-dependent vector DNA levels in cell lysates. Untransduced cells showed background levels of approximately E3 gc / ug DNA. APOE variant protein expression was confirmed in culture supernatants of cells transduced with 1E+06 gc / cell by Western blotting ( Fig.11 B).

[0247] Example 7: WT mouse studies investigating the expression of AAV5 / AAV9 APOE3ch-HA.

[0248] In order to study the expression of APOE3ch in C57B16 mice, 8 mice per group were injected with a single bilateral intrastriatal dose of AAV5 or AAV9 vector, or a single bilateral intraventricular injection of AAV5 or AAV9 vector. All AAV vectors carry the APOE3ch expression cassette with double HA tags. In the 4th week after treatment, animals were killed, and the vector DNA level and mRNA level in the striatum of the brain were determined. On average, the AAV5 and AAV9 groups receiving the vector in the striatum (IS) expressed 6e7 and 2e7 genome copies / ug DNA. The AAV group delivered intraventricularly (ICV) showed slightly lower vector genome copies, respectively, AAV5 was 4e6 copies, and AAV9 was 3e6 copies (12A). Determine the mRNA copy number in the striatum of the brain of all animals. The IS AAV5 and AAV9 groups expressed an average of 6e8 and 8e8 copies of mRNA in the striatum of the brain, while the ICV group showed slightly lower mRNA expression levels; 1.1e8 copies for the AAV5 group and 1.5e8 copies for the AAV9 group ( Fig.12 B).

[0249] Example 8: Effects of APOE overexpression in different brain regions in the P301S tauopathy model

[0250] The efficacy of AAV5 vectors encoding different APOE variants in altering the phenotype of the tauopathy model P301S mice was evaluated by a single bilateral intrastriatal injection of AAV5 vectors. Two-month-old male mice were treated by a single bilateral intrastriatal administration of vehicle (0.001% Pluronic F-68) and empty AAV5, AAV5-APOE2chWT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3ch V2 and AAV5-APOE3b V2 (SEQ ID NO.197, 208, 210, 209 and 211) at a dose of 3E11 gc / mouse. An untreated wild-type (WT) littermate control group was also included. The effect of the AAV5-APOE vector will be evaluated by behavioral tests. Seven months after infusion, molecular analysis of different brain regions, CSF, plasma and liver was performed on 8-11 animals per group. For 1-4 animals per group, brains were fixed for histological purposes.

[0251] AAV transduction and APOE transcript expression were analyzed by quantifying vector DNA and APOE mRNA levels in the striatum by RT-qPCR. Mice treated with AAV5-APOE2chWT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3ch V2, and AAV5-APOE3b V2 all showed a significant increase in vector DNA levels up to 4.67E+07 gc / μg DNA and APOE mRNA levels up to 4.48E+09 copies / μg RNA compared to WT, vehicle, and empty AAV5 groups (Figure 21A-Figure 21B).

[0252] In order to examine whether the increased mRNA copy levels in the APOE variant treatment group are consistent with the increased APOE protein expression, hAPOE-MSD was performed on hippocampal and frontal cortex tissues (Figure 21C-Figure 21D). hAPOE protein levels were not detected in WT, vehicle, and empty AAV5 groups. In AAV5-APOE2ch WT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3chV2, and AAV5-APOE3b V2 groups, elevated hAPOE protein levels were detected in both the hippocampus (up to 511.09ng / mg) and the frontal cortex (up to 2086.41ng / mg). Compared with other groups, AAV5-APOE2ch WT administration resulted in the highest production of APOE protein, which is a pattern previously observed in vitro ( Fig.15 ).

[0253] Soluble total tau protein and phosphorylated tau protein were examined to understand whether the expression of APOE variants affects the level of pathogenic phosphorylated tau protein. Separate MSD assays were performed to quantify total tau protein and pTau181 on hippocampal tissue. Total tau protein was detected at comparable levels in all P301S mouse groups except the WT group (Figure 22A). When compared to the vehicle group, a significant reduction in pTau181 levels was detected in AAV5-APOE2ch WT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3ch V2, and AAV5-APOE3bV2 groups (up to 55%, Figure 22B-Figure 22C). Examination of the quantitative relationship between pTau181 and total tau protein levels ( FIGS. 22D-22E ) revealed up to 70% reduction in the pTau181 / total tau protein ratio for the AAV5-APOE2ch V2, AAV5-APOE2b V2, and AAV5-APOE3b V2 groups when compared to the vehicle group.

[0254] Based on these results, we expected that immunohistochemistry would reveal changes in the levels of phosphorylated tau protein, neurofibrillary tangles, and the number of astrocytes and microglia in the hippocampus of mice injected with AAV5 vectors encoding different APOE variants compared to vehicle and / or empty AAV5 injected groups. As a common finding of these immunohistochemical studies, we expected to detect changes in the size of the ventricular cavity in the brains of vehicle and / or empty AAV5 injected groups compared to the WT group, and changes in the size of the ventricular cavity in the brains of mice injected with AAV5 vectors encoding different APOE variants compared to vehicle and / or empty AAV5 injected groups.

[0255] Together, these results demonstrate that administration of AAV5-APOE variants results in high and comparable vDNA and mRNA levels, leading to increased APOE protein levels and decreased pTau181 levels.

[0256] Example 9: In vitro testing of combinatorial constructs - reporter reduction

[0257] To test the ability to simultaneously silence APOE4 and overexpress APOE2 or APOE3 variants, HEK293T cells were co-transfected with the combined expression construct and the APOE luciferase reporter. miAPOE or APOE variant expression plasmids were used as controls.

[0258] In the first screen, HEK293T cells were co-transfected with 86.54 fmol of the combinatorial constructs (SEQ ID NO. 255-276), APOE variants (SEQ ID NO. 197, 208, 210, 211) or miAPOE (SEQ ID NO. 108, 116, 146, 186) and 10 fmol of the reporter. Expression of all combinatorial constructs (SEQ ID NO. 255-276; Table 6) resulted in knockdown of the luciferase reporter ( Fig.13 To further evaluate the efficacy of the different constructs, titration experiments were performed using 0.69, 3.46 and 17.31 fmol (corresponding to 2, 10 or 50 ng, see Example 1) of the DNA construct. Dose-dependent reductions were visible for all tested constructs ( Fig.14 ).

[0259] Table 6. Combination constructs.

[0260]

[0261]

[0262]

[0263]

[0264]

[0265]

[0266]

[0267]

[0268]

[0269]

[0270]

[0271]

[0272]

[0273]

[0274]

[0275]

[0276]

[0277]

[0278]

[0279]

[0280]

[0281] Example 10: In vitro testing of combinatorial constructs - APOE expression

[0282] In addition, APOE protein expression in the supernatant of cells transfected with the combined constructs was quantified by ELISA. Protein quantification was assessed only for the supernatant of cells transfected with the highest amount (e.g., 86.54 fmol) of the DNA construct. APOE protein expression was confirmed for all transfected cells ( Fig.15 ).

[0283] Example 11: In vivo testing of combined constructs delivered by AAV in P301S / hAPOE4-TR mice

[0284] The efficacy of AAV5 vectors encoding combined expression constructs as well as single constructs in altering the phenotype of the tauopathy model P301S mice that also carry the hAPOE4 gene (P301S / hAPOE4-TR mice) will be evaluated by single bilateral intrastriatal injections of AAV vectors. The effects of AAV vectors will be evaluated by behavioral tests and molecular analysis of different brain regions, CSF, plasma, and liver.

[0285] We expected that in the group administered with the AAV vector, vDNA levels and APOE variant mRNA / miRNA expression would be detected in the brain. In fact, it was expected that miRNA levels would be elevated in the brain of the group injected with the construct containing miAPOE, while the group administered with the construct containing the APOE variant transgene was predicted to display elevated APOE variant mRNA.

[0286] Furthermore, it is expected that decreased or altered levels of hAPOE4, tau protein, and phosphorylated tau protein will be observed in the brain of the AAV vector-injected group compared to the vehicle group.

[0287] Example 12: In vivo testing of combination approach constructs delivered by AAV in WT mice

[0288] The expression level of transgenes of combination method constructs and single constructs mediated by AAV5 (4.3E10 gc / mouse) delivery was evaluated by a single bilateral intrastriatal injection in WT mice. Male mice were treated with AAV5 combination method constructs and single constructs with IDs 2, 3, 16 and 18 (SEQ ID NO.256, 257, 270 and 272, respectively), including AAV5-APOE2chV2 expression variants (SEQ ID NO.208), AAV5-miSCR (SEQ ID NO.186), AAV5-miAPOE_016 (SEQ IDNo.108) and AAV5-miAPOE_037 (SEQ ID NO.116). Empty AAV5 was included as a control. Animals were sacrificed one month after treatment. Multiple brain regions and livers of 5-6 animals per group were collected and snap frozen.

[0289] The vector DNA level was quantified by qPCR to analyze AAV transduction. Except for the empty AAV5 treatment group, all groups showed a considerable and significant increase in the vector DNA level in the striatum, reaching up to 3.74E+07gc / μg DNA (Figure 23A). The miRNA level was quantified by SYBR green RT-qPCR using specific primers of mature miSCR and miAPOE with 23, 24 or 25 nucleotides in length (Figure 23B). The selected primers and standard systems (Figure 20A) were optimized based on the previous small RNA sequencing results. The miRNA level in the striatum of the group injected with the combination method vector reached up to 1.48E+09 copies / μg total RNA (Figure 23B). The miRNA level of the AAV5-miSCR group was similar to the combination method construct group. The miAPOE copy levels in the AAV5-miAPOE_016 group reached as high as 7.06E+09 copies / μg total RNA, while the miRNA levels of the AAV5-miAPOE_037 and empty AAV5 groups did not result in levels above the LLOQ. This assay was not performed on tissues from the AAV5-APOE2ch V2 group, as no miRNA was expected.

[0290] hAPOE mRNA expression in the striatum of all groups was evaluated via RT-qPCR (Figure 23C). Elevated expression of hAPOE mRNA up to 1.22E+10 copies / μg RNA was detected in the group expressing the combined method construct, and 7.08E+08 copies / μg RNA was detected in the AAV5-APOE2ch V2 group. It is expected that no mRNA will be detected in the WT, AAV5-miSCR, AAV5-miAPOE_016 and AAV5-miAPOE_037 groups, although the assay does detect mRNA copies slightly above the LLOQ.

[0291] To examine whether the increased mRNA copy levels in the group injected with the combined method vector and AAV5-APOE2ch V2 were consistent with increased APOE protein expression, hAPOE-MSD was performed on the snout cortex tissue (Figure 23D). No hAPOE protein levels were detected in the empty AAV5, AAV5-miSCR, AAV5-miAPOE_016, and AAV5-miAPOE_037 groups. Up to 478.83ng / mg hAPOE protein levels were detected in the group injected with the combined method vector, while the hAPOE protein level in the AAV5-APOE2ch V2 group reached 129.48ng / mg protein level.

[0292] In summary, these in vivo results demonstrated high levels of vDNA between all groups and demonstrated similar or higher transcript and protein levels for the combinatorial approach constructs compared to constructs expressing single transcripts.

[0293] Example 13: AAV5 Combination Methods Constructs and In Vitro Transduction of AAV5-miAPOE to Examine miAPOE Processing and Decapping Target Effect

[0294] To examine the processing and abundance of miAPOE expressed by the combinatorial method constructs and single miAPOE constructs in human-derived glioblastoma cells, U-118MG cells were transduced with AAV5 combinatorial method constructs ID 2 and 16 (SEQ ID NOs. 256 and 270), AAV5-miSCR (SEQ ID NO. 186), AAV5-miAPOE_016 (SEQ ID NO. 108), AAV5-miAPOE_037 (SEQ ID NO. 116), and AAV5-miAPOE_145 (SEQ ID NO. 146). miAPOE_016 was encoded in combinatorial method construct ID 2, and miAPOE_145 was encoded in combinatorial method construct ID 16. Three days after transduction, RNA was isolated from these cell cultures and analyzed by small RNA sequencing and poly A-enriched mRNA sequencing.

[0295] Data analysis revealed that read counts for the expected miAPOE transcripts for the combined method constructs, miAPOE_016 and miAPOE_145, ranged from 2.68% to 0.05% when compared to total miRNA reads (Figure 24B). There were no read counts for miAPOE_037.

[0296] The most abundant isomiRs generated by the combined method constructs, miAPOE_016 and miAPOE_145, were all 24 nucleotides long (Figure 24A). The total miAPOE reads of all constructs except miAPOE_037 were compared with the expression levels of endogenous miRNAs (Figure 24C). Considering that miAPOE is not among the most abundant endogenously expressed miRNAs, the risk of miAPOE oversaturating the RNAi pathway is very low. The two internal controls, miR-29a-3p and miR-16-5p, showed consistent abundance in all samples, ranking 6.33±1.55 (SD) and 19.75±6.13 (SD), respectively (marked in Figure 24C).

[0297] Differential expression analysis was performed to reveal the potential off-target effects of the combined method, miAPOE_016 and miAPOE_145 constructs. miSCR was used as a control, and analysis was performed to determine the degree of difference of other constructs at the transcript level. This revealed that the transcript expression differences of all samples were very small, with FDR p value>0.05 (Figure 24D). As expected, the combined method constructs had significantly increased APOE transcripts. Although the combined method construct ID 16 did not have other differentially expressed transcripts, ID 2 had two genes whose transcript levels deviated from the control. Both miAPOE_016 and miAPOE_145 had one and the same differentially expressed gene.

[0298] In summary, these in vitro results revealed normal processing of miAPOE expressed by the combinatorial approach and single constructs. Minimal to no off-target effects were observed within the transcriptome of samples expressing these miAPOEs.

[0299] Example 14: In silico assessment of potential off-target transcripts of miAPOE miRNA guides

[0300] Computer simulation analysis of possible off-target gene transcripts was performed on the miAPOE miRNA guide sequence (BLASTN) and the guide seed sequence (siSPOTR). Short sequence BLASTN (via ENSEMBL) was performed for the human reference transcriptome to identify transcripts with partial complementarity of at least 7 consecutive nucleotides within the miAPOE guide sequence (SEQ ID NO.108, 116 and 146) of 22 nucleotides. Except for APOE, no gene transcripts were found that were fully complementary to the miAPOE miRNA guide sequence of 22 nucleotides. Gene transcripts with partial complementarity were sorted by alignment scores, which were calculated from the sum of the rewards for matching nucleotides and the penalties for mismatches and gaps (matches / mismatches: 1 / -3). The top 15 hits (Table 9) are shown below.

[0301] The siSPOTR tool (Boudreau et al., 2013) was used to predict the binding of miAPOE miRNA guide seed sequences (nucleotides 2-8 of the 5'-3' guide sequence) to potential off-target gene transcripts, which are mainly found in the 3'UTR of the target transcript. Potential off-target scores (POTS) were calculated using seed site type frequencies (8-mer, 7-mer-M8, 7-mer-1A and 6-mer) (Table 10). The list of possible off-target genes was sorted by the probability of off-target score (tPOTS) of individual transcripts. tPOTS was calculated based on the number and type of seed matches found in individual transcripts. The first 15 hits of potential off-target genes are listed in Table 11.

[0302] None of the top 15 hits for potential off-targets of the miAPOE guide seed sequence overlapped with the top 15 hits predicted by in silico off-targets of the miAPOE guide sequence by BLASTN of short sequences. The in silico predicted transcripts were found to be not significantly differentially expressed in the RNA-seq data from AAV5 combinatorial approach constructs IDs 2 and 16 (SEQ ID NOs. 256 and 270), AAV5-miAPOE_016 (SEQ ID NO. 108), and AAV5-miAPOE_145 (SEQ ID NO. 146) ( FIG. 24D ).

[0303] Table 9: Top 15 hits for in silico off-target prediction of miAPOE guide sequences by BLASTN of short sequences. Alignment length: number of nucleotides of individual gene transcripts complementary to a 22-nucleotide miAPOE guide sequence with 0, 1 or 2 mismatches or gaps; Score: alignment score calculated from the sum of the reward for matching nucleotides and the penalty for mismatches or gaps; ID%: percentage of identity complementary to the miAPOE guide sequence relative to the aligned sequence length.

[0304]

[0305]

[0306]

[0307] Table 10. In silico off-target prediction of miAPOE guide seed sequences by SiSPOTR: potential off-targets by seed match type. Seed match type: 8-mer site (perfect match to nucleotides 2-8 followed by A), 7-mer-m8 site (perfect match to nucleotides 2-8), 7-mer-1A (perfect match to nucleotides 2-7 followed by A), 6-mer site (perfect match to nucleotides 2-7); Potential off-target score (POTS) was calculated using seed site type frequencies (8-mer, 7-mer-M8, 7-mer-1A, and 6-mer).

[0308]

[0309] Table 11: Top 15 hits from in silico off-target predictions of miAPOE guide seed sequences by siSPOTR

[0310] tPOTS: Off-target probability score; Number of seed match types: 8-mer site (perfect match to nucleotides 2-8 followed by A), 7-mer-m8 site (perfect match to nucleotides 2-8), 7-mer-1A (perfect match to nucleotides 2-7 followed by A), 6-mer site (perfect match to nucleotides 2-7); Potential off-target score (POTS) was calculated using the seed site type frequencies (8-mer, 7-mer-M8, 7-mer-1A, and 6-mer).

[0311]

[0312]

[0313]

[0314] References

[0315] Knouff C,Hinsdale ME,et al.Apo E structure determines VLDL clearance and atherosclerosis risk in mice.J Clin Invest.1999Jun;103(11):1579-86.doi:10.1172 / JCI6172.PMID:10359567;PMCID:PMC408371.

[0316] Sullivan PM,Mezdour H,et al.Targeted replacement of the mouseapolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.J Biol Chem.1997Jul 18;272(29):17972-80.doi:10.1074 / jbc.272.29.17972.PMID:9218423.

[0317] Arboleda-Velasquez JF,Lopera F,et al.Resistance to autosomal dominantAlzheimer's disease in an APOE3 Christchurch homozygote:a case report.NatMed.2019Nov;25(11):1680-1683.doi:10.1038 / s41591-019-0611-3.Epub2019Nov4.PMID:31686034.

[0318] van den Maagdenberg AM,Weng W,et al.Characterization of five newmutants in the carboxyl-terminal domain of human apolipoprotein E:nocosegregation with severe hyperlipidemia.Am J Hum Genet.1993May;52(5):937-46.PMID:8488843.

[0319] Liu CC,Murray ME,et al.APOE3-Jacksonville(V236E)variant reduces self-aggregation and risk of dementia.Sci Transl Med.2021Sep 29;13(613):eabc9375.doi:10.1126 / scitranslmed.abc9375.Epub 2021Sep 29.PMID:34586832.

[0320] BLAST.Joseph Bedell,Ian Korf and Mark Yandell[OReilly&Associates,2003],Altschul SF,Gish W,Miller W,Myers EW,Lipman DJ.Basic local alignmentsearch tool.J Mol Biol.1990;215(3):403-410.doi:10.1016 / S0022-2836(05)80360-2

[0321] Boudreau RL,Spengler RM,Hylock RH,Kusenda BJ,Davis HA,Eichmann DA,Davidson BL.siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse.Nucleic Acids Res.2013Jan 7;41(1):e9.doi:10.1093 / nar / gks797.Epub 2012Aug 31.PMID:22941647; PMCID:PMC3592398. BRIEF DESCRIPTION OF THE DRAWINGS

[0322] Figure 1. Schematic representation of a portion of the APOE4 cDNA sequence that is part of the following NCBI reference sequence: NM_000041. The depicted sequence is referred to herein as SEQ ID NO. 1, and corresponds to nucleotides 1-1166 thereof, and represents the DNA sequence of (a portion of) the spliced ​​APOE transcript (transcript 2).

[0323] Figure 2 . Schematic diagram of the scaffold RNA structure indicating the first RNA sequence, as designed in (a) and (b).

[0324] Figure 3 Validation of the miR-144A>T mutant scaffold by small mRNA sequencing. A) Comparison of the expression levels of miRNA6 (=miHTT), miR-144 5p, miR-144 3p, and miR-16 in miR-451, miR-144 wild type (WT), and miR-144A>T mutant scaffolds. B) Comparison of the expression values ​​of a set of different miRNA sequences inserted into the miR-451 and miR-144A>T mutant scaffolds.

[0325] Figure 4 . In vitro knockdown of APOE4 Luc reporter by miAPOE in HEK293T cells after co-transfection with 250 ng of DNA constructs (SEQ ID NOs. 94-185).

[0326] Figure 5In vitro knockdown of APOE4 Luc reporter by 25 miAPOE constructs (SEQ ID NO. 96, 99, 100, 105, 106, 108, 109, 113, 114, 115, 116, 117, 131, 132, 133, 134, 135, 136, 137, 139, 143, 146, 149, 151, 185) after co-transfection with 2, 10 or 50 ng of DNA construct. The relative Renilla expression (RL / FL) of miSCR441 (SEQ ID NO. 186) was set to 100%.

[0327] Figure 6 . In vitro expression and reduction of endogenous APOE mRNA in Huh7 cells after transfection with 250 ng of miAPOE constructs (SEQ ID NO. 94-185).

[0328] Figure 7 . In vitro expression and reduction of endogenous APOE mRNA after transfection with 50 or 250 ng of miAPOE constructs (SEQ ID NOs. 96, 108, 116, 133, 136, 138, 146, 151, 185) or miSCR constructs (SEQ ID NOs. 186-187) (n=2).

[0329] Figure 8 .(A) Western blot and (B) its relative quantification showing secreted endogenous APOE protein (reduction) in the supernatant of Huh7 cells transfected with miAPOE constructs (SEQ ID NOs 96, 108, 116, 136, 146, 185) or miSCR construct (SEQ ID NO. 186).

[0330] Fig. 9 Knockdown of vector DNA copies and APOE mRNA expression in Huh7 cells after transduction with AAV5 or AAV9 containing miAPOE expression cassette (SEQ ID NO. 108, 116, 146). Huh7 cells were transduced at a multiplicity of infection (MOI) of 5E+06, 3.6+06, 1E+06, 5E+05 or 5E+04 gc / cell. (A) Vector DNA copy number and (B) APOE mRNA expression were determined 48 h after transduction. APOE mRNA expression in the presence of AAV5-miSCR (SEQ ID No. 186) was set to 100%.

[0331] Fig.10In vitro Western blotting of APOE protein in culture supernatants of HEK293T cells and astrocytoma cells 48 h after transfection with 250 ng of APOE variant expression constructs.

[0332] Fig.11 . Vector DNA copies and APOE protein expression in the culture supernatant of HEK293T cells transduced with AAV5 containing APOE variant expression cassettes (SEQ ID NO. 197, 208, 210, 209, 211). HEK293T cells were transduced at a multiplicity of infection (MOI) of 1E4, 1E5 or 1E6. (A) Vector DNA copies in transduced HEK293T cells. (B) APOE protein detection in the supernatant of AAV-transduced HEK293T cells by Western blot.

[0333] Fig.12 . Detection of vector DNA (A) and mRNA copies (B) in the striatum of the brains of C57B16 mice injected with AAV-APOE3ch.-HA.

[0334] Fig.13 . In vitro silencing of the APOE4 luc reporter by the combinatorial approach and miAPOE constructs after co-transfection with the reporter (10 fmol) and either the combinatorial approach (SEQ ID NOs. 255-276, labeled 1-22) or the miAPOE constructs (SEQ ID NOs. 108, 116, 146).

[0335] Fig.14 In vitro silencing of the APOE4 luc reporter by the combinatorial approach constructs after co-transfection with the reporter (2.18 fmol) and 0.69, 3.46 or 17.31 fmol of the combinatorial approach DNA constructs (SEQ ID NOs. 255-276, labeled 1-22) or miAPOE constructs (SEQ ID NOs. 108, 116, 146). The relative Renilla expression (RL / FL) of the combinatorial approach containing miSCR441 was set to 100%.

[0336] Fig.15 . APOE transgene expression in the supernatant of Hek293T cells transfected with the combinatorial method constructs (SEQ ID NOs. 255-276, labeled 1-22) or APOE transgene constructs (SEQ ID NOs. 197, 208, 210, 211).

[0337] Fig.16. Expression of vector DNA in the striatum (A) and frontal cortex (B) of mice injected with high (gray bars) or medium (white bars) doses of empty AAV5, AAV5-miSCR, AAV5-miAPOE_016, AAV5-miAPOE_037, AAV5-miAPOE_145, or AAV9-miAPOE_145.

[0338] Figure 17. Knockdown of APOE4 mRNA in the striatum (AB) and frontal cortex (CD) of mice injected with high (grey bars) or medium (white bars) doses of AAV5-miAPOE_016, AAV5-miAPOE_037, AAV5-miAPOE_145 or AAV9-miAPOE_145 compared to empty AAV5 and AAV5-miSCR. (B, D) Relative AAV5-miSCR copy levels were set to 100%.

[0339] Fig.18 . miRNA copy levels in the striatum of mice injected with high (grey bars) or medium (white bars) doses of AAV5-miSCR, AAV5-miAPOE_016, AAV5-miAPOE_037, AAV5-miAPOE_145, or AAV9-miAPOE_145.

[0340] Fig.19 . Reduction of hAPOE4 protein in the frontal cortex of mice injected with high (grey bars) or medium (white bars) doses of AAV5-miAPOE_016, AAV5-miAPOE_037, AAV5-miAPOE_145, or AAV9-miAPOE_145 compared with empty AAV5 and AAV5-miSCR.

[0341] Figure 20. (A) Abundance of read lengths compared to total miAPOE reads found in the caudal cortex of hAPOE4-Tr mice injected with AAV5-miAPOE_016, AAV5-miAPOE_037, and AAV5-miAPOE_145. The most abundant read lengths for miAPOE_016, miAPOE_037, and miAPOE_145 were 23, 25, and 24 nucleotides, respectively. (B) Read counts for miAPOE transcripts. (C) Ranking abundance of endogenous miRNAs and miAPOE detected in the caudal cortex of hAPOE4-Tr mice injected with AAV5-miSCR, AAV5-miAPOE_016, AAV5-miAPOE_037, and AAV5-miAPOE_145. Internal controls miR-29a-3p and miR-16-5p are marked with a single or double asterisk, respectively.

[0342] Figure 21. Expression of vector DNA (A) and APOE mRNA (B) in the striatum of WT or P301S mice injected with vehicle, empty AAV5, AAV5-APOE2ch WT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3ch V2, and AAV5-APOE3b V2. The dotted line indicates LLOQ. (C-D) hAPOE protein levels detected in the hippocampus (C) and frontal cortex (D) of WT or P301S mice injected with vehicle, empty AAV5, AAV5-APOE2ch WT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3ch V2, and AAV5-APOE3b V2.

[0343] Figure 22. (A) Total tau protein levels in the hippocampus of WT or P301S mice injected with vehicle, empty AAV5, AAV5-APOE2ch WT, AAV5-APOE2ch V2, AAV5-APOE2bV2, AAV5-APOE3ch V2, and AAV5-APOE3b V2. (BC) pTau181 protein levels in the hippocampus of WT or P301S mice injected with vehicle, empty AAV5, AAV5-APOE2ch WT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3chV2, and AAV5-APOE3bV2. Measured values ​​(B) and normalized values ​​(C) demonstrate that pTau181 levels are significantly reduced in all groups injected with AAV5-APOE variants. By one-way ANOVA, **P<0.01, ***P<0.001. The dotted line indicates 50%. (DE) pTau181 / total tau protein ratio in the hippocampus of WT or P301S mice injected with vehicle, empty AAV5, AAV5-APOE2ch WT, AAV5-APOE2ch V2, AAV5-APOE2b V2, AAV5-APOE3ch V2, and AAV5-APOE3b V2. The measured values ​​(D) and normalized values ​​(E) reveal that the pTau181 / total tau protein ratio is significantly reduced in the groups injected with AAV5-APOE2ch V2, AAV5-APOE2b V, and AAV5-APOE3b V2. By one-way ANOVA, **P<0.01, ****P<0.0001. The dotted line indicates 50%.

[0344] Figure 23. Expression of vector DNA in the striatum of WT mice injected with the combination method and single constructs encapsulated in AAV5 (A) and miAPOE copy levels (B). APOE mRNA copy levels in the striatum of WT mice injected with the combination method and single constructs encapsulated in AAV5 (C) and APOE protein levels in the cortex (D). The dotted line indicates LLOQ.

[0345] Figure 24. (A) Abundance of read lengths compared to total miAPOE reads found in U-118MG cell cultures transduced with AAV5 combo method construct IDs 2 and 16, AAV5-miAPOE_016, and AAV5-miAPOE_145. The most abundant read length for all constructs was 24 nucleotides. (B) Read counts for miAPOE transcripts. (C) Ranked abundance of endogenous miRNAs and miAPOE detected in U-118MG cell cultures transduced with AAV5 combo method construct IDs 2 and 16, AAV5-miSCR, AAV5-miAPOE_016, and AAV5-miAPOE_145. Internal controls miR-29a-3p and miR-16-5p are marked with single or double asterisks, respectively. (D) Differential expression analysis of combined approach, miAPOE_016 and miAPOE_145 constructs.

Claims

1. A nucleic acid comprising a sequence encoding a first RNA and a sequence encoding a second RNA, wherein the second RNA comprises a guide sequence of at least 19 nucleotides that is substantially complementary to a portion of an ApoE gene, and wherein the first RNA and the second RNA each comprise a hairpin.

2. The nucleic acid according to claim 1, wherein In the 5' to 3' direction, the sequence encoding the first RNA is followed by a spacer, which is followed by the sequence encoding the second RNA, and wherein the spacer is at least 50 nucleotides.

3. The nucleic acid of claim 1 or claim 2, wherein the hairpin in the second RNA comprises at least 40 nucleotides.

4. The nucleic acid according to any one of claims 1 to 3, wherein the first RNA comprises SEQ ID NO. 235 or a variant thereof, and the second RNA comprises SEQ ID NO. 190 or a variant thereof.

5. The nucleic acid of any one of claims 1 to 4, wherein the guide sequence is at least 22 nucleotides.

6. The nucleic acid of any one of claims 1 to 5, wherein the guide sequence is specific for a portion of the ApoE4 gene.

7. The nucleic acid according to any one of claims 1 to 6, wherein the guide sequence is substantially complementary to a sequence selected from SEQ ID NO. 16, 24, 54.

8. The nucleic acid according to any one of claims 1 to 7, wherein the first RNA is mutated to reduce processing and / or expression of the first RNA.

9. An expression cassette comprising the nucleic acid according to any one of claims 1 to 8, wherein the expression cassette is a DNA molecule.

10. The expression cassette according to claim 9, further comprising a second nucleic acid encoding at least one of APOE2 and APOE3, wherein the first nucleic acid and the second nucleic acid are operably linked to a promoter and optionally to a poly A signal, wherein preferably, the second nucleic acid encodes a protein comprising one of SEQ ID NOs 249-254 and / or the second nucleic acid comprises one of SEQ ID NOs. 195-217.

11. The expression cassette according to claim 10, wherein the second nucleic acid does not comprise a sequence that is substantially complementary to a guide sequence as defined in any one of claims 1 to 7, wherein preferably the nucleotide sequence is codon-optimized for expression in human cells.

12. An expression cassette according to claim 10 or claim 11, wherein the second nucleic acid comprises a sequence selected from SEQ ID NOs. 195-217.

13. The expression cassette according to any one of claims 10 to 12, wherein the sequence encoding the first RNA and the sequence encoding the second RNA are contained in intron sequences.

14. The expression cassette according to claim 13, wherein an intron sequence is present in the promoter, wherein preferably the intron sequence comprises SEQ ID NO.

231.

15. The expression cassette according to any one of claims 9 to 14, wherein the promoter is a promoter capable of driving transcription in brain cells, wherein preferably, the promoter comprises one of SEQ ID NO. 191, 192, 193 or 232.

16. The expression cassette according to any one of claims 9 to 15, wherein the expression cassette is flanked by inverted terminal repeats (ITRs).

17. An adeno-associated virus (AAV) vector comprising the expression cassette according to claim 16.

18. The AAV vector of claim 17, comprising an AAV5 or AAV9 capsid protein.

19. A pharmaceutical composition comprising a nucleic acid according to any one of claims 1 to 8, or an expression cassette according to claims 9 to 16, or an AAV vector according to claim 17 or claim 18 and at least one pharmaceutically acceptable excipient.

20. A nucleic acid according to any one of claims 1 to 8, or an expression cassette according to claims 9 to 16, or an AAV vector according to claim 17 or claim 18, or a pharmaceutical composition according to claim 19, for use as a medicament.

21. A nucleic acid according to any one of claims 1 to 8, or an expression cassette according to claims 9 to 16, or an AAV vector according to claim 17 or claim 18, or a pharmaceutical composition according to claim 19, for use in treating and / or preventing Alzheimer's disease in a subject.

22. The nucleic acid according to any one of claims 1 to 8, or the expression cassette according to claims 9 to 16, or the AAV vector according to claim 17 or claim 18, or the pharmaceutical composition according to claim 19 for use according to claim 20, wherein the subject is a carrier of the ApoE4 allele, wherein preferably the subject is homozygous for the ApoE4 allele.

23. The nucleic acid according to any one of claims 1 to 8, or the expression cassette according to claims 9 to 16, or the AAV vector according to claim 17 or claim 18, or the pharmaceutical composition according to claim 19 for use according to claim 20 or 21, wherein the nucleic acid, the expression cassette, the AAV vector or the pharmaceutical composition is preferably administered to the central nervous system by intracerebral injection, intraparenchymal injection, intrathecal injection or a combination thereof, more preferably by convection enhanced delivery.

24. A kit comprising a nucleic acid according to any one of claims 1 to 8, or an expression cassette according to claims 9 to 16, or an AAV vector according to claim 17 or claim 18, or a pharmaceutical composition according to claim 19, wherein the kit further comprises an immunosuppressant.

25. An expression cassette comprising a nucleic acid encoding one or more APOE2 and APOE3 proteins selected from SEQ ID NOs. 249-254 for use in gene therapy.

26. The expression cassette of claim 25, wherein the one or more proteins are encoded by a nucleic acid sequence comprising at least part of a wild-type sequence.

27. The expression cassette of claim 25, wherein the one or more proteins are encoded by a nucleic acid sequence comprising a full-length wild-type coding sequence.

28. The expression cassette for use according to claim 25, wherein the expression cassette comprises one or more nucleic acid sequences selected from SEQ ID NO. 195-201, the one or more nucleic acid sequences optionally being operably linked to a promoter and a poly A signal.

29. The expression cassette of claims 25 to 28, wherein the expression cassette is flanked by ITRs.

30. An adeno-associated virus (AAV) vector comprising the expression cassette of any one of claims 25 to 29.

31. The AAV vector of claim 30, comprising an AAV5 or AAV9 capsid protein.

32. A pharmaceutical composition comprising the AAV vector according to claim 30 or claim 31 and at least one pharmaceutically acceptable excipient.

33. An expression cassette according to claims 25 to 29, or an AAV vector according to claim 30 or claim 31, or a pharmaceutical composition according to claim 32, for use in treating and / or preventing Alzheimer's disease in a subject.

34. An expression cassette according to claims 25 to 29, or an AAV vector according to claim 30 or claim 31, or a pharmaceutical composition according to claim 32 for use according to claim 33, wherein the subject is a carrier of the ApoE4 allele, wherein preferably the subject is homozygous for the ApoE4 allele.

35. The expression cassette according to claims 25 to 29, or the AAV vector according to claim 30 or claim 31, or the pharmaceutical composition according to claim 32 for use according to claim 33, wherein the expression cassette, the AAV vector or the pharmaceutical composition is preferably administered to the central nervous system by intracerebral injection, intraparenchymal injection, intrathecal injection or a combination thereof, more preferably by convection enhanced delivery.

36. A kit comprising an expression cassette according to claims 25 to 29, or an AAV vector according to claim 30 or claim 31, or a pharmaceutical composition according to claim 3, wherein the kit further comprises an immunosuppressant.